[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 108
1. Villafañe MF, Trione N, Corti M, Mendez N, Gancedo E, Zamora N, Levin M: Primary liver AIDS-related lympoma. Rev Inst Med Trop Sao Paulo; 2006 Jul-Aug;48(4):229-31
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary liver AIDS-related lympoma.
  • Non-Hodgkin's lymphomas (NHL) are the second most frequent malignancies in AIDS patients.
  • The majority of NHL associated with AIDS involves extranodal sites, especially the digestive tract and the central nervous system.
  • Primary liver lymphoma (PLL) is an uncommon neoplasm among these patients.
  • We report a case of PLL as the initial manifestation of AIDS in a patient without any previous infection by hepatitis C or B virus, presented as multiple and large hepatic masses.
  • [MeSH-major] Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119682.001).
  • [ISSN] 0036-4665
  • [Journal-full-title] Revista do Instituto de Medicina Tropical de São Paulo
  • [ISO-abbreviation] Rev. Inst. Med. Trop. Sao Paulo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


2. Mayor AM, Gómez MA, Ríos-Olivares E, Hunter-Mellado RF: AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy. Ethn Dis; 2008;18(2 Suppl 2):S2-189-94
MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-defining neoplasm prevalence in a cohort of HIV-infected patients, before and after highly active antiretroviral therapy.
  • Implementation of highly active antiretroviral therapy (HAART) has resulted in a dramatic reduction in the HIV/AIDS morbidity and mortality.
  • The present study evaluates the neoplasm prevalence before and after the implementation of HAART.
  • Neoplasm prevalence was measured, and the difference in AIDS- and non-AIDS-defining neoplasms was analyzed before and after the HAART era.
  • Of these, 51.5% were AIDS-defining neoplasms, and 68% were established before HAART.
  • AIDS-defining neoplasms accounted for 62.4% of those detected before the availability of HAART and 25.9% of those detected after HAART.
  • Except for cervical carcinoma, the prevalence of AIDS-defining neoplasms decreased after HAART.
  • Non-AIDS lymphomas and prostate neoplasms were more frequent after HAART.
  • DISCUSSION: Our study found a significant reduction of Kaposi sarcoma and AIDS-related lymphoma in the HAART era of the AIDS epidemic.
  • A higher prevalence of non-AIDS-defining lymphomas, prostate carcinoma, and cervical carcinoma was seen in the HAART era.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Thorax. 2006 Nov;61(11):1000-8 [17071836.001]
  • [Cites] MMWR Suppl. 1987 Aug 14;36(1):1S-15S [3039334.001]
  • [Cites] J Behav Med. 2007 Oct;30(5):371-83 [17570050.001]
  • [Cites] J Clin Oncol. 2006 Jun 1;24(16):2417-9 [16735700.001]
  • [Cites] Ann Intern Med. 2006 Sep 19;145(6):397-406 [16983127.001]
  • [Cites] JAMA. 2000 Jul 12;284(2):223-8 [10889597.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30 [11078759.001]
  • [Cites] J Acquir Immune Defic Syndr. 2001 Apr 15;26(5):480-2 [11391169.001]
  • [Cites] Oncology (Williston Park). 2002 May;16(5):657-65; discussion 665, 668-70 [12108891.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 21;94(16):1204-10 [12189223.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3447-53 [12972519.001]
  • [Cites] AIDS. 2003 Oct 17;17(15):2227-36 [14523280.001]
  • [Cites] Clin Infect Dis. 2004 Nov 1;39(9):1380-4 [15494916.001]
  • [Cites] Ethn Dis. 2005 Autumn;15(4 Suppl 5):S5-57-62 [16312941.001]
  • [Cites] Curr HIV Res. 2004 Oct;2(4):343-9 [15544455.001]
  • [Cites] J Acquir Immune Defic Syndr. 1999 Aug 1;21 Suppl 1:S34-41 [10430217.001]
  • [Cites] MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19 [1361652.001]
  • [Cites] Clin Infect Dis. 2003 Apr 15;36(8):1030-8 [12684916.001]
  • (PMID = 18646347.001).
  • [ISSN] 1049-510X
  • [Journal-full-title] Ethnicity & disease
  • [ISO-abbreviation] Ethn Dis
  • [Language] ENG
  • [Grant] United States / NIMHD NIH HHS / MD / G12 MD007583; United States / NCRR NIH HHS / RR / U54 RR019507; United States / NCRR NIH HHS / RR / G12RR03035; United States / NCRR NIH HHS / RR / 1U54RR01950701; United States / NCRR NIH HHS / RR / G12 RR003035
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS425729; NLM/ PMC3546505
  •  go-up   go-down


3. Corti M, Solari R, Cangelosi D, De Carolis L, Schtirbu R, Lewi D: Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution. Rev Soc Bras Med Trop; 2007 Sep-Oct;40(5):582-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral cavity lymphoma as secondary AIDS-defining neoplasm in a patient on HAART with immune reconstitution.
  • Lymphomas of the oral cavity are a rare complication of advanced HIV/AIDS disease.
  • We report the case of a patient with AIDS who developed diffuse large B-cell non-Hodgkins lymphoma of the oral cavity during highly active antiretroviral therapy, with undetectable plasma viral load and immune reconstitution.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Mouth Neoplasms / diagnosis


Advertisement
4. Vilchez RA, Lopez-Terrada D, Middleton JR, Finch CJ, Killen DE, Zanwar P, Jorgensen JL, Butel JS: Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma. Virology; 2005 Nov 10;342(1):38-46
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simian virus 40 tumor antigen expression and immunophenotypic profile of AIDS-related non-Hodgkin's lymphoma.
  • To investigate the possible production of the viral transforming protein, we examined age-matched case-control specimens from patients with HIV/AIDS for the expression of SV40 large tumor antigen (T-ag).
  • A germinal center B-cell-like (GCB) profile was more frequently expressed by SV40-positive tumors than in Epstein-Barr virus (EBV)-related lymphomas (10/12, 83% vs. 6/13, 46%; P = 0.05), whereas a non-GCB phenotype was more frequent in EBV-positive than in SV40-positive lymphomas (7/13, 54% vs. 2/12, 17%; P = 0.05).
  • This study shows that SV40 gene expression occurs in a fraction of cells in some B-cell lymphomas among patients with HIV/AIDS.
  • [MeSH-major] Antigens, Polyomavirus Transforming / genetics. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adult. Base Sequence. Case-Control Studies. DNA, Viral / genetics. DNA, Viral / isolation & purification. Female. Gene Expression. Genes, Viral. HIV-1. Humans. Immunophenotyping. Male. Middle Aged. Molecular Sequence Data. Neoplasm Recurrence, Local / immunology. Neoplasm Recurrence, Local / virology. Simian virus 40 / genetics. Simian virus 40 / isolation & purification

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16122775.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36211; United States / NCI NIH HHS / CA / CA104818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / DNA, Viral
  •  go-up   go-down


5. Mounier N, Spina M, Gabarre J, Raphael M, Rizzardini G, Golfier JB, Vaccher E, Carbone A, Coiffier B, Chichino G, Bosly A, Tirelli U, Gisselbrecht C: AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy. Blood; 2006 May 15;107(10):3832-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy.
  • We aimed to compare AIDS risk-adapted intensive chemotherapy in AIDS-related lymphoma (ARL) patients before and after the advent of highly active antiretroviral therapy (HAART).
  • A total of 485 patients aged from 18 to 67 years were randomly assigned to chemotherapy after stratification according to an HIV score based on performance status, prior AIDS, and CD4(+) cell counts below 0.10 x 10(9)/L (100/mm(3)).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisolone / administration & dosage. Risk Assessment. Survival Analysis. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2006 Nov 15;108(10):3621; author reply 3621-2 [17085718.001]
  • (PMID = 16410446.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  •  go-up   go-down


6. Sissolak G, Mayaud P: AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa. Trop Med Int Health; 2005 Oct;10(10):981-92
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: epidemiological, diagnostic, treatment and control aspects in sub-Saharan Africa.
  • Until the 1980s, little attention had been accorded to endemic Kaposi's sarcoma (KS), a neoplasm noted in several parts of Southern Europe and the African continent but with relatively slow progression, except in children and young adults.
  • With the emergence of the HIV/AIDS epidemic, and the profound impact of KS on AIDS-related mortality, the pathogenesis of KS has been better studied, and the realisation that a virus (KS-associated Herpesvirus or Human Herpesvirus 8, or KSHV/HHV-8), combined with immunosuppression and cytokine-induced growth, was responsible for the development of this disease has led to novel therapeutic approaches.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185232.001).
  • [ISSN] 1360-2276
  • [Journal-full-title] Tropical medicine & international health : TM & IH
  • [ISO-abbreviation] Trop. Med. Int. Health
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  • [Number-of-references] 95
  •  go-up   go-down


7. Dhillon T, Stebbing J, Bower M: Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev Anticancer Ther; 2005 Apr;5(2):215-9
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paclitaxel for AIDS-associated Kaposi's sarcoma.
  • Treatment options are limited for patients with advanced acquired immunodeficiency syndrome-related Kaposi's sarcoma (AIDS-KS).
  • The management of early stage cutaneous AIDS-KS has been revolutionized by the introduction of highly active antiretroviral therapy and for most patients highly active antiretroviral therapy alone will control early stage AIDS-KS.
  • For patients with refractory or recurrent AIDS-KS, treatment algorithms are less well defined.
  • [MeSH-minor] Algorithms. Anti-Retroviral Agents / therapeutic use. Herpesviridae Infections / complications. Humans. Neoplasm Recurrence, Local / drug therapy. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15877519.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents; 0 / Antineoplastic Agents, Phytogenic; P88XT4IS4D / Paclitaxel
  • [Number-of-references] 54
  •  go-up   go-down


8. Mantovani A, Allavena P, Sica A, Balkwill F: Cancer-related inflammation. Nature; 2008 Jul 24;454(7203):436-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cancer-related inflammation.
  • In some types of cancer, inflammatory conditions are present before a malignant change occurs.
  • Conversely, in other types of cancer, an oncogenic change induces an inflammatory microenvironment that promotes the development of tumours.
  • It aids in the proliferation and survival of malignant cells, promotes angiogenesis and metastasis, subverts adaptive immune responses, and alters responses to hormones and chemotherapeutic agents.
  • The molecular pathways of this cancer-related inflammation are now being unravelled, resulting in the identification of new target molecules that could lead to improved diagnosis and treatment.
  • [MeSH-minor] Gonadal Steroid Hormones / metabolism. Humans. Leukocytes / immunology. Leukocytes / metabolism. Neoplasm Invasiveness. Oncogenes / genetics. Oncogenes / physiology

  • Archivio Istituzionale della Ricerca Unimi. Full text from AIR - Univ. Milan .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18650914.001).
  • [ISSN] 1476-4687
  • [Journal-full-title] Nature
  • [ISO-abbreviation] Nature
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0501974; United Kingdom / Cancer Research UK / / ; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gonadal Steroid Hormones
  • [Number-of-references] 98
  •  go-up   go-down


9. Bower M, Weir J, Francis N, Newsom-Davis T, Powles S, Crook T, Boffito M, Gazzard B, Nelson M: The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma. AIDS; 2009 Aug 24;23(13):1701-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of HAART in 254 consecutive patients with AIDS-related Kaposi's sarcoma.
  • OBJECTIVE: A prospective cohort study was performed to evaluate the clinical outcomes of patients with histologically confirmed AIDS-related Kaposi's sarcoma diagnosed since the introduction of HAART.
  • Seventy-nine (31%) patients had AIDS clinical Trial Group stage T1 disease at Kaposi's sarcoma diagnosis and 122 (48%) had AIDS clinical Trial Group stage I1 disease (CD4 cell count < 150 cells/microl).
  • Nodular grade Kaposi's sarcoma represented 28% of the tumours and was significantly associated with black African ethnicity and AIDS clinical Trial Group T1 stage disease.
  • CONCLUSION: The high success rate of HAART in a large cohort of AIDS-Kaposi's sarcoma patients over a prolonged period of follow-up will reassure patients and clinicians that this is a well tolerated and effective approach to stage T0 Kaposi's sarcoma.
  • [MeSH-minor] Adolescent. Adult. Aged. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome. Viral Load. Young Adult


10. Pantanowitz L, Schwartz EJ, Dezube BJ, Kohler S, Dorfman RF, Tahan SR: C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma. Appl Immunohistochem Mol Morphol; 2005 Jun;13(2):162-6
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C-Kit (CD117) expression in AIDS-related, classic, and African endemic Kaposi sarcoma.
  • Kaposi sarcoma (KS) is a multicentric vascular neoplasm characterized histologically by the progressive proliferation of spindle-shaped tumor cells in all epidemiologic (AIDS-related, classic, endemic, and iatrogenic) forms.
  • Archival cases of formalin-fixed, paraffin-embedded KS lesions, including 9 classic, 11 AIDS-related, and 15 African (endemic) forms at various histologic stages (5 patch, 8 plaque, 22 nodular), biopsied from different sites, were stained using immunohistochemistry with antibodies to HHV8 (LNA-1) and c-kit (CD117).
  • A total of five (56%) classic, five (45%) AIDS-related, and five (33%) endemic KS cases were positive for c-kit.
  • HHV8 (LNA-1) immunoreactivity was present in all (100%) classic, 10 (91%) AIDS-related, and 9 (60%) endemic cases.


11. Mbulaiteye SM, Sternberg LR, Nsubuga MM, Anver MR, Mehta M, Biryahwaho B, Kambugu F, Rabkin CS, Biggar RJ: Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma. Cancer Lett; 2007 Apr 18;248(2):229-33
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of Y-chromosome sequences in tumors from African women with AIDS-related Kaposi sarcoma.
  • Kaposi sarcoma (KS) occurs with relatively high frequency in immunosuppressed transplant recipients and in patients with AIDS.
  • Recently, Italian investigators reported transplant-related KS tumors bearing donor-derived antigens, suggesting possible parenteral transmission of KS as whole cells, i.e., chimeric tumors.
  • To investigate the hypothesis that KS whole cells may also be transmitted into immunocompromised persons via heterosexual acts, we tested nodular KS lesions and matched normal tissue obtained from female patients with AIDS for the presence of the Y-chromosome specific sex determining sequence (SRY).
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. DNA, Neoplasm / genetics. Disease Transmission, Infectious. Sarcoma, Kaposi / genetics. Sex-Determining Region Y Protein / analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16934394.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CO / N01 CO12400; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Sex-Determining Region Y Protein
  •  go-up   go-down


12. Martellotta F, Berretta M, Vaccher E, Schioppa O, Zanet E, Tirelli U: AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies. Curr HIV Res; 2009 Nov;7(6):634-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma: state of the art and therapeutic strategies.
  • In the HAART era Kaposi's sarcoma (KS) remains the second most frequent tumor in HIV-infected patients worldwide, and it has become the most common cancer in Sub-Saharan Africa.
  • KS lesions are comprised of both distinctive spindle cells of endothelial origin and a variable inflammatory infiltrate, which suggests that KS may result from reactive hyperproliferation induced by chronic inflammation, and therefore it is not a true neoplasm.
  • Treatment decisions must take into consideration the extent and the rate of tumor growth, patient's symptoms, immune system conditions and concurrent HIV-related complications.
  • The aim of this article is to provide an up-to-date review of the current status and perspectives of AIDS-related KS in the HAART era.


13. Konstantinopoulos PA, Sullivan RJ, Karamouzis MV, Dezube BJ: Investigational agents for treatment of AIDS-related Kaposi's sarcoma. Expert Opin Investig Drugs; 2007 Apr;16(4):495-504
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigational agents for treatment of AIDS-related Kaposi's sarcoma.
  • AIDS-related Kaposi's sarcoma (KS) is a neoplasm that results from the co-infection of HIV and KS herpesvirus/human herpesvirus-8 (KSHV/HHV8).
  • Recent discoveries have elucidated the role of multiple signaling pathways in the pathogenesis of AIDS-related KS.
  • This article discusses the main signaling pathways that are implicated in the pathogenesis of AIDS-related KS, reviews recently completed clinical trials and anticipates the future direction of molecularly targeted agents in this disease.


14. Orem J, Otieno MW, Remick SC: Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa. Curr Opin Oncol; 2006 Sep;18(5):479-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Challenges and opportunities for treatment and research of AIDS-related malignancies in Africa.
  • PURPOSE OF REVIEW: Following our review of AIDS-associated cancer in developing nations in 2004, we sought to update recent publications and review data on the challenges and opportunities for the treatment and research of AIDS malignancies in Africa.
  • RECENT FINDINGS: It is apparent that the burden of AIDS-related malignancies and other virus-associated tumors is significant and increasing in Africa.
  • Several recent studies report findings on conjunctival squamous cell carcinoma and there is a report that Hodgkin's disease, a non-AIDS-defining neoplasm, is increasing in incidence.
  • International collaborative partnerships dedicated to AIDS malignancies in developing countries are feasible and invaluable for clinical strategies to address this aspect of the pandemic.
  • A departure point is the ongoing work of the East Africa - Case Western Reserve University Collaboration in AIDS malignancies.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16894296.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI36219; United States / NCI NIH HHS / CA / CA43703; United States / NCI NIH HHS / CA / CA70081; United States / NCI NIH HHS / CA / CA83528; United States / FIC NIH HHS / TW / TW00011
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 56
  •  go-up   go-down


15. Aboulafia DM, Ratner L, Miles SA, Harrington WJ Jr, AIDS Associated Malignancies Clinical Trials Consortium: Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019. Clin Lymphoma Myeloma; 2006 Mar;6(5):399-402
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antiviral and immunomodulatory treatment for AIDS-related primary central nervous system lymphoma: AIDS Malignancies Consortium pilot study 019.
  • PURPOSE: A consistent association with Epstein-Barr Virus (EBV) distinguishes acquired immunodeficiency syndrome (AIDS)-related primary central nervous system lymphoma (PCNSL) from that which occurs in the general population.
  • PATIENTS AND METHODS: We enrolled 4 patients with AIDS-related PCNSL into a novel antiviral and immunomodulatory protocol.
  • All 6 patients had advanced-stage AIDS as reflected by a CD4+ T-lymphocyte cell count of < 50/microL and a detectable human immunodeficiency virus (HIV)-1 viral RNA load (median copies, 135,000/mL; range, 2170-360,000/mL).
  • CONCLUSION: We conclude that for patients with AIDS and PCNSL, treatments with dual efficacy against HIV and EBV merit further investigation.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. Brain Neoplasms / drug therapy. Brain Neoplasms / mortality. Interleukins / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Lymphoma, AIDS-Related / mortality
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Positron-Emission Tomography. Prospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome


16. Corti M, de Dios Soler M, Bare P, Villafañe MF, De Tezanos Pinto M, Perez Bianco R, Narbaitz M: [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8]. Medicina (B Aires); 2010;70(2):151-8
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [AIDS related lymphomas: Histopathological subtypes and association with Epstein Barr virus and Human Herpes virus type-8].
  • Non-Hodgkin lymphomas (NHL) of the B-cell type are the second most common neoplasm among patients with human immunodeficiency virus (HIV) infection and AIDS.
  • Here, we evaluated 48 cases of AIDS-related lymphomas (ARL) diagnosed at the Histopathological Division of the Instituto de Investigaciones Hematológicas of the National Academy of Medicine.
  • All were fenotype B cell lymphomas with an aggressive course and advanced neoplasm disease at the time of diagnosis.
  • Virological findings showed the strong association between EBV and AIDS-related NHL.
  • We consider that all cases of AIDS related lymphomas should be assessed for the presence of EBV because its presence may play a role in the prognosis.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / genetics. Hodgkin Disease / virology. Lymphoma, AIDS-Related / virology. Lymphoma, Non-Hodgkin / virology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20447898.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


17. Autier J, Picard-Dahan C, Marinho E, Grossin M, Yeni P, Leport C, Vildé JL, Crickx B, Descamps V: Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study. Br J Dermatol; 2005 May;152(5):1026-9
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel in anthracycline-pretreated AIDS-related Kaposi's sarcoma: a retrospective study.
  • BACKGROUND: Kaposi's sarcoma (KS) is a potentially life-threatening multifocal neoplasm.
  • Despite the significant decline in the incidence of acquired immune deficiency syndrome (AIDS)-related KS with the use of highly active antiretroviral therapy (HAART), some patients, even those with a good immune restoration, still have aggressive disease.
  • OBJECTIVES: We studied the efficacy and tolerance of docetaxel in the treatment of AIDS-related KS after pretreatment with anthracycline.
  • Tumour response was evaluated using the AIDS Clinical Trial Group (ACTG) staging criteria.
  • AIDS status with HIV viral load and CD4 T-cell count were measured at the beginning and at the end of the treatment.
  • CONCLUSIONS: Docetaxel has a good and rapid efficacy in anthracycline-pretreated patients with severe AIDS-related KS.


18. Corti M, Villafañe Fioti MF, Lewi D, Schtirbu R, Narbaitz M, de Dios Soler M: [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients]. Acta Gastroenterol Latinoam; 2006 Dec;36(4):190-6
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-Hodgkin's lymphomas of the digestive tract and anexal glands in AIDS patients].
  • BACKGROUND: Non-Hodgkin's lymphoma (NHL) is the second most common neoplasm among patients with AIDS.
  • One of the major clinical characteristics of AIDS-associated NHL is the high frequency of extra-nodal involvement, including the gastrointestinal tract, at initial presentation.
  • METHODS: From January 1997 to December 2004, 8 cases of NHL of the digestive tract and anexal glands (liver and parotid gland) were observed at the HIV/AIDS division of the Infectious Diseases FJ Muñiz Hospital from Buenos Aires, Argentina.
  • The median age was 42 years and the median CD4 T cell count was 87 cells/uL at the time of the diagnosis of neoplasm.
  • The global incidence of AIDS-associated lymphomas (central nervous system lymphomas, non-Hodgkin lymphomas and Hodgkin lymphoma) during the time of study was 2,9% (54 cases); 17 patients (32%) had diagnosis of systemic NHL; 10 (58,8%) of them were extranodal at the onset of clinical symptoms and 8 (80%) involvement the digestive tract and anexal glands (parotid gland, cavum, esophagus, stomach, duodenum, the right colon in 2 patients and the liver), as primary NHL of high grade and "B" phenotype.
  • CONCLUSION: NHL of the gastrointestinal tract is a severe complication of advanced HIV/AIDS disease.
  • [MeSH-major] Gastrointestinal Neoplasms / diagnosis. Liver Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Parotid Neoplasms / diagnosis
  • [MeSH-minor] Adult. Female. Humans. Male. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225446.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


19. Dezube BJ, Krown SE, Lee JY, Bauer KS, Aboulafia DM: Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study. J Clin Oncol; 2006 Mar 20;24(9):1389-94
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi's sarcoma: an AIDS Malignancy Consortium Study.
  • In a phase I trial of the MMP inhibitor COL-3 in patients with AIDS-related KS, the drug was well tolerated, KS regression was observed, and MMP-2 levels decreased significantly in responders compared with nonresponders.
  • COL-3 was administered orally once daily at one of two doses (group A received 50 mg and group B received 100 mg) to patients with AIDS-related KS.
  • CONCLUSION: COL-3, when administered as 50 mg/d, is both active and well tolerated in the treatment of AIDS-related KS.
  • COL-3 is a promising agent for the treatment of this opportunistic neoplasm of AIDS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16549833.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U01CA070019; United States / NCI NIH HHS / CA / U01CA070047; United States / NCI NIH HHS / CA / U01CA070054; United States / NCI NIH HHS / CA / U01CA070062; United States / NCI NIH HHS / CA / U01CA070072; United States / NCI NIH HHS / CA / U01CA070079; United States / NCI NIH HHS / CA / U01CA070080; United States / NCI NIH HHS / CA / U01CA071375; United States / NCI NIH HHS / CA / U01CA083038; United States / NCI NIH HHS / CA / U01CA083118; United States / NCI NIH HHS / CA / U01CA083216; United States / NCI NIH HHS / CA / U01CA70058; United States / NCI NIH HHS / CA / U01CA70081
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tetracyclines; 0 / tetracycline CMT-3; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


20. Miralles Alonso F, Ortega González LM, Oropesa González L, Francisco RD, de Paz VC: [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005]. Rev Cubana Med Trop; 2006 Sep-Dec;58(3):248-53
Genetic Alliance. consumer health - HIV.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Behaviour of HIV/AIDS-related lymphoma in Pedro Kouri Institute. 2004-2005].
  • It called our attention that high levels of lactic acid dehydrogenase and extrapulmonary location of tumors were related.
  • [MeSH-major] Lymphoma, AIDS-Related / epidemiology
  • [MeSH-minor] Academies and Institutes. Adult. Biomarkers, Tumor / blood. Blood Sedimentation. CD4 Lymphocyte Count. Cuba / epidemiology. Ethnic Groups / statistics & numerical data. Female. Humans. Immunocompromised Host. L-Lactate Dehydrogenase / blood. Male. Neoplasm Staging. Prospective Studies. Risk Factors. Viral Load. Viremia / epidemiology. Young Adult

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 23424794.001).
  • [ISSN] 0375-0760
  • [Journal-full-title] Revista cubana de medicina tropical
  • [ISO-abbreviation] Rev Cubana Med Trop
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Cuba
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


21. Ruff KR, Puetter A, Levy LS: Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6. BMC Cancer; 2007 Feb 26;7:35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Growth regulation of simian and human AIDS-related non-Hodgkin's lymphoma cell lines by TGF-beta1 and IL-6.
  • BACKGROUND: AIDS-related non-Hodgkin's lymphoma (AIDS-NHL) is the second most frequent cancer associated with AIDS, and is a frequent cause of death in HIV-infected individuals.
  • Experimental analysis of AIDS-NHL has been facilitated by the availability of an excellent animal model, i.e., simian Acquired Immunodeficiency Syndrome (SAIDS) in the rhesus macaque consequent to infection with simian immunodeficiency virus.
  • The authors concluded that TGF-beta acts as a negative growth regulator of the lymphoma-derived cell line and, potentially, as an inhibitory factor in the regulatory network of AIDS-related lymphomagenesis.
  • The present study was conducted to assess whether other SAIDS-NHL and AIDS-NHL cell lines are similarly sensitive to the growth inhibitory effects of TGF-beta, and to test the hypothesis that interleukin-6 (IL-6) may represent a counteracting positive influence in their growth regulation.
  • Intracellular flow cytometry was used to analyze the activation of signaling pathways and to examine the expression of anti-apoptotic proteins and distinguishing hallmarks of AIDS-NHL subclass.
  • By comparison, human AIDS-NHL cell lines differed in their responsiveness to TGF-beta1 and IL-6.
  • Analysis of a recently derived AIDS-NHL cell line, UMCL01-101, indicated that it represents immunoblastic AIDS-DLCBL.
  • CONCLUSION: These studies indicate that the sensitivity of immunoblastic AIDS- or SAIDS-DLBCL to TGF-beta1-mediated growth inhibition may be overcome through the stimulation of proliferative and anti-apoptotic signals by IL-6, particularly through the rapid activation of STAT3.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS Res Hum Retroviruses. 1999 Nov 1;15(16):1477-85 [10555111.001]
  • [Cites] J Biol Chem. 1999 Aug 13;274(33):23013-9 [10438468.001]
  • [Cites] AIDS Res Hum Retroviruses. 2000 Jan 20;16(2):163-71 [10659055.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2468-73 [10851045.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2496-504 [10851048.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2548-56 [10851053.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]
  • [Cites] Semin Oncol. 2000 Aug;27(4):431-41 [10950370.001]
  • [Cites] J Immunol. 2000 Sep 1;165(5):2500-10 [10946276.001]
  • [Cites] Leuk Lymphoma. 2000 Aug;38(5-6):481-8 [10953968.001]
  • [Cites] Blood. 2000 Dec 15;96(13):4084-90 [11110677.001]
  • [Cites] FEBS Lett. 2001 Jan 19;488(3):179-84 [11163768.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):709-23 [11297268.001]
  • [Cites] Oncogene. 2001 Feb 8;20(6):677-85 [11314001.001]
  • [Cites] Oncogene. 2001 May 3;20(20):2499-513 [11420660.001]
  • [Cites] AIDS Res Hum Retroviruses. 2001 May 20;17(8):745-51 [11429114.001]
  • [Cites] J Med Virol. 2001 Sep;65(1):114-20 [11505452.001]
  • [Cites] Oncogene. 2001 Sep 13;20(41):5799-809 [11593385.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):945-54 [11948098.001]
  • [Cites] Blood. 2002 Jul 1;100(1):194-9 [12070027.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):316-26 [12538484.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):3867-72 [12553006.001]
  • [Cites] Int J Cancer. 2003 Jul 10;105(5):661-8 [12740915.001]
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] Biochem J. 2003 Aug 15;374(Pt 1):1-20 [12773095.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1731-7 [12970772.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6639-45 [14528289.001]
  • [Cites] Rev Physiol Biochem Pharmacol. 2003;149:1-38 [12687404.001]
  • [Cites] J Virol. 2004 Feb;78(4):1697-705 [14747535.001]
  • [Cites] Vet Pathol. 1988 Nov;25(6):456-67 [2850650.001]
  • [Cites] Int J Cancer. 1999 Nov 12;83(4):564-70 [10508495.001]
  • [Cites] AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1389-98 [10515154.001]
  • [Cites] J Biol Chem. 2005 Mar 18;280(11):10491-500 [15637055.001]
  • [Cites] Oncogene. 2005 Mar 24;24(13):2121-43 [15789036.001]
  • [Cites] Br J Haematol. 2005 Sep;130(5):662-70 [16115121.001]
  • [Cites] Cell Res. 2005 Nov-Dec;15(11-12):947-52 [16354573.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Biol Chem. 2006 Apr 14;281(15):10153-63 [16478725.001]
  • [Cites] Blood. 1992 Jul 15;80(2):498-504 [1320956.001]
  • [Cites] Blood. 1994 Feb 15;83(4):1067-78 [8111047.001]
  • [Cites] Oncogene. 1995 Oct 19;11(8):1615-22 [7478586.001]
  • [Cites] J Interferon Cytokine Res. 1995 Mar;15(3):261-8 [7584673.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):40-3 [8548771.001]
  • [Cites] Virology. 1995 Dec 20;214(2):431-8 [8553544.001]
  • [Cites] Blood. 1996 Aug 1;88(3):809-16 [8704235.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Nov 1;13(3):215-26 [8898666.001]
  • [Cites] Immunity. 1996 Nov;5(5):449-60 [8934572.001]
  • [Cites] Blood. 1997 Feb 1;89(3):941-7 [9028325.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5877-81 [9159168.001]
  • [Cites] AIDS Res Hum Retroviruses. 1997 Dec 10;13(18):1589-96 [9430251.001]
  • [Cites] J Virol. 1998 Jun;72(6):5182-8 [9573290.001]
  • [Cites] Br J Haematol. 1998 Oct;103(1):143-9 [9792301.001]
  • [Cites] Immunity. 1999 Jan;10(1):105-15 [10023775.001]
  • [Cites] Br J Haematol. 1999 Nov;107(2):392-5 [10583232.001]
  • (PMID = 17324269.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074731; United States / NCI NIH HHS / CA / R01 CA74731
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1
  • [Other-IDs] NLM/ PMC1810304
  •  go-up   go-down


22. Hernández-Morales DE, Hernández-Zaccaro AE: Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions. Eur J Cancer Care (Engl); 2005 Jul;14(3):264-6
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
  • Kaposi's sarcoma (KS) continues to be a frequent neoplasm in third world AIDS patients.
  • The study included 15 male AIDS patients aged between 25 and 35 years (mean: 27 years) with more than 25 cutaneous lesions and extensive gastrointestinal KS.

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15952971.001).
  • [ISSN] 0961-5423
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 80168379AG / Doxorubicin
  •  go-up   go-down


23. Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL: Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol; 2005 Dec;29(12):1633-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm.
  • AIDS-associated aggressive B-cell lymphomas often have plasmacytoid features.
  • [MeSH-major] HIV Seropositivity. Herpesvirus 4, Human / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Multiple Myeloma / pathology


24. Galicier L, Fieschi C, Borie R, Meignin V, Daniel MT, Gérard L, Oksenhendler E: Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study. Blood; 2007 Oct 15;110(8):2846-54
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy regimen (LMB86) for St Jude stage IV AIDS-related Burkitt lymphoma/leukemia: a prospective study.
  • Prognosis of acquired immunodeficiency syndrome (AIDS)-related non-Hodgkin lymphoma has improved since the introduction of highly active antiretroviral therapy.
  • Seven treatment-related deaths occurred and all patients experienced severe BM toxicity.
  • We conclude that LMB86 regimen is highly effective in advanced HIV-related BL and should be proposed for patients with CD4 count higher than 200 x 10(6)/L or ECOG of 2 or less.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Burkitt Lymphoma / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Kaplan-Meier Estimate. Male. Methotrexate / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Prospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17609431.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


25. Oji C, Chukwuneke F: Clinical evaluation of Kaposi sarcoma in HIV/AIDS patients with orofacial lesions in Enugu, Nigeria. J Oral Maxillofac Surg; 2008 Jul;66(7):1362-5
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical evaluation of Kaposi sarcoma in HIV/AIDS patients with orofacial lesions in Enugu, Nigeria.
  • PURPOSE: To highlight the association of Kaposi sarcoma (KS) with HIV/AIDS in patients of the oral and maxillofacial surgery units of 2 specialist hospitals in Enugu, Nigeria.
  • PATIENTS AND METHODS: The case notes of 112 patients who had HIV/AIDS lesions in the orofacial region were retrieved from the medical records department of 2 specialist hospitals.
  • We studied the clinical, histopathologic, and therapeutic aspects of these AIDS-related KS cases over a period of 4 years, from January 2000 to December 2003.
  • RESULTS: There were 33 cases of KS and they ranged highest out of the total number of cases (112) cases that had HIV/AIDS.
  • CONCLUSION: KS is strongly associated with HIV/AIDS in our environment.
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Middle Aged. Neoplasm Staging. Nigeria. Patient Acceptance of Health Care. Retrospective Studies. Sexual Behavior


26. da Silva Filho FP, Marchiori E, Valiante PM, Escuissato DL, Gasparetto TD: AIDS-related Kaposi sarcoma of the lung presenting with a "crazy-paving" pattern on high-resolution CT: imaging and pathologic findings. J Thorac Imaging; 2008 May;23(2):135-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi sarcoma of the lung presenting with a "crazy-paving" pattern on high-resolution CT: imaging and pathologic findings.
  • Kaposi sarcoma (KS) is a fulminate and disseminated form of acquired immunodeficiency syndrome (AIDS)-defining neoplasm, usually presenting pulmonary involvement.
  • We report a 40-year-old woman with AIDS and biopsy-proven KS showing unusual high-resolution computed tomography (HRCT) findings.
  • The authors suggest the inclusion of KS in the differential diagnosis of lung diseases in patients with AIDS presenting with crazy-paving pattern on the HRCT.


27. Roma AA, Goldblum JR, Fazio V, Yang B: Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma. Int J Clin Exp Pathol; 2008;1(5):419-25
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of 14-3-3sigma, p16 and p53 proteins in anal squamous intraepithelial neoplasm and squamous cell carcinoma.
  • 14-3-3sigma is a p53-regulated G2/M inhibitor involved in numerous cellular signaling pathways related to cell cycle, DNA repair and apoptosis.
  • However, the expression of 14-3-3sigma protein has not yet been studied in anal SCC and its precursor, anal intraepithelial neoplasm (AIN).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Mar;24(3):429-41 [10716158.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] J Low Genit Tract Dis. 2007 Jan;11(1):46-7 [17194951.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):463-8 [16894294.001]
  • [Cites] Cancer Res. 2000 Aug 15;60(16):4353-7 [10969776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3105-10 [16886641.001]
  • [Cites] Am J Surg Pathol. 2006 Jul;30(7):795-801 [16819320.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):183-92 [16697662.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):225-34 [16697215.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):161 [16697214.001]
  • [Cites] Mol Cell Proteomics. 2005 Jun;4(6):785-95 [15778465.001]
  • [Cites] Histopathology. 2005 Jun;46(6):718-20 [15910611.001]
  • [Cites] J Low Genit Tract Dis. 2005 Apr;9(2):108-13 [15870532.001]
  • [Cites] Cell Res. 2005 Apr;15(4):228-36 [15857577.001]
  • [Cites] Pathol Int. 2005 Feb;55(2):77-82 [15693853.001]
  • [Cites] AIDS Read. 2005 Feb;15(2):79-82, 85-6, 88, 91 [15712398.001]
  • [Cites] Hum Pathol. 2004 Dec;35(12):1477-83 [15619206.001]
  • [Cites] Int J Oncol. 2004 Dec;25(6):1591-7 [15547695.001]
  • [Cites] Semin Cancer Biol. 1998;8(5):345-57 [10101800.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] J Natl Cancer Inst. 1994 Nov 16;86(22):1711-6 [7966400.001]
  • [Cites] Pathol Int. 2004 Oct;54(10):743-50 [15482563.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1131-8 [15292943.001]
  • [Cites] Int J Gynecol Pathol. 2004 Jul;23(3):206-14 [15213596.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2687-93 [15102672.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Oncogene. 2002 Mar 14;21(12):1876-81 [11896620.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45193-200 [11577088.001]
  • [Cites] Int J Gynecol Pathol. 2001 Jan;20(1):16-30 [11192069.001]
  • [Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]
  • (PMID = 18787619.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2480570
  • [Keywords] NOTNLM ; 14-3-3σ / AIN / Anal intraepithelial neoplasm / Bowenoid / differentiated / p16 / p53 / simplex
  •  go-up   go-down


28. Jabr FI: Recurrent lymphoma presenting as a penile ulcer in a patient with AIDS. Dermatol Online J; 2005;11(2):29
MedlinePlus Health Information. consumer health - Penis Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent lymphoma presenting as a penile ulcer in a patient with AIDS.
  • Penile lymphoma is a rare neoplasm.
  • We report a 45-year-old man with history of AIDS and previous retroperitoneal lymphoma who presented with painless penile ulceration and multiple inguinal lymphadenopathy.
  • [MeSH-major] Lymphoma, AIDS-Related / pathology. Neoplasm Recurrence, Local / pathology. Penile Diseases / etiology. Penile Diseases / pathology. Penile Neoplasms / etiology. Penile Neoplasms / pathology. Ulcer / etiology. Ulcer / pathology

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16150237.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  •  go-up   go-down


29. Ferrazzo KL, Mesquita RA, Aburad AT, Nunes FD, de Sousa SO: EBV detection in HIV-related oral plasmablastic lymphoma. Oral Dis; 2007 Nov;13(6):564-9
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EBV detection in HIV-related oral plasmablastic lymphoma.
  • OBJECTIVES: Plasmablastic lymphoma (PBL) of the oral cavity is an aggressive neoplasm derived from B cell, considered to be the second more common among human immunodeficiency virus (HIV)-associated malignancies.
  • As Epstein-Barr virus (EBV) infection has been associated with this neoplasm, the aim of the present study was to assess the presence of EBV in 11 cases of oral HIV-related PBL and investigate the controversial issue of the presence of Human herpesvirus-8 (HHV-8) in these tumors.
  • CONCLUSION: The presence of EBV in all cases studied favors a direct role of this virus in the development of HIV-related PBL, and this finding could be considered when dealing with HIV patients.
  • [MeSH-major] DNA, Viral / analysis. Herpesvirus 4, Human / isolation & purification. Lymphoma, AIDS-Related / virology. Mouth Neoplasms / virology

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17944673.001).
  • [ISSN] 1354-523X
  • [Journal-full-title] Oral diseases
  • [ISO-abbreviation] Oral Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


30. Corti M, Villafañe MF, Souto L, Schtirbu R, Narbaitz M, Soler Mde D: Burkitt's lymphoma of the duodenum in a patient with AIDS. Rev Soc Bras Med Trop; 2007 May-Jun;40(3):338-40
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Burkitt's lymphoma of the duodenum in a patient with AIDS.
  • Non-Hodgkin's lymphoma of B-cell type is the second most common neoplasm after Kaposi's sarcoma, among patients with human immunodeficiency virus infection.
  • We report a case of primary lymphoma of the duodenum in a patient with AIDS.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Duodenal Neoplasms / diagnosis. Lymphoma, AIDS-Related / diagnosis

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Burkitt's Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17653472.001).
  • [ISSN] 0037-8682
  • [Journal-full-title] Revista da Sociedade Brasileira de Medicina Tropical
  • [ISO-abbreviation] Rev. Soc. Bras. Med. Trop.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


31. Corti M, Villafañe MF, Palmieri O, Aisencher D, Sawicki M, Schtirbu R, Narbaitz M, Soler Mde D: [Ileocolic intussusception due to a large B cell lymphoma in a patient with AIDS]. Acta Gastroenterol Latinoam; 2008 Mar;38(1):51-5
MedlinePlus Health Information. consumer health - Small Intestine Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ileocolic intussusception due to a large B cell lymphoma in a patient with AIDS].
  • Here, we describe a case of an AIDS adult patient who developed an ileocolic intussusception secondary to a large B cell lymphoma of the cecum.
  • Surgical findings included the ileon free of the tumor and invaginated within the cecum with infiltrating neoplasm.
  • [MeSH-major] Cecal Neoplasms / complications. Ileal Diseases / etiology. Intussusception / etiology. Lymphoma, AIDS-Related / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533357.001).
  • [ISSN] 0300-9033
  • [Journal-full-title] Acta gastroenterologica Latinoamericana
  • [ISO-abbreviation] Acta Gastroenterol. Latinoam.
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


32. Gilaberte M, Gallardo F, Bellosillo B, Saballs P, Barranco C, Serrano S, Pujol RM: Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma. Br J Dermatol; 2005 Oct;153(4):828-32
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent and self-healing cutaneous monoclonal plasmablastic infiltrates in a patient with AIDS and Kaposi sarcoma.
  • We report a 44-year-old man with AIDS and Kaposi sarcoma (KS) previously treated with doxorubicin who, following treatment with highly active antiretroviral therapy, developed an erythematous infiltrated nodule on the right arm.
  • PBL may be seen in patients with transplants or receiving chemotherapy, but is usually observed in patients with advanced AIDS.
  • The observation of recurrent self-healing EBV- and HHV-8-associated cutaneous monoclonal plasmablastic infiltrates, in a patient with AIDS and KS, expands the clinical spectrum of AIDS-associated plasmablastic lymphoproliferative disorders.
  • [MeSH-major] Acquired Immunodeficiency Syndrome / complications. Epstein-Barr Virus Infections / complications. Herpesvirus 8, Human. Lymphoma, AIDS-Related / virology. Sarcoma, Kaposi / complications
  • [MeSH-minor] Adult. Humans. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Neoplasm Regression, Spontaneous. Recurrence

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181470.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Huysentruyt LC, McGrath MS: The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma. J Leukoc Biol; 2010 Apr;87(4):627-32
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of macrophages in the development and progression of AIDS-related non-Hodgkin lymphoma.
  • Additionally, TAM are known to promote tumor progression for most cancer types, including lymphomas.


34. Vega MI, Martinez-Paniagua M, Jazirehi AR, Huerta-Yepez S, Umezawa K, Martinez-Maza O, Bonavida B: The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs. Leuk Lymphoma; 2008 Oct;49(10):1982-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NF-kappaB inhibitors (bortezomib and DHMEQ) sensitise rituximab-resistant AIDS-B-non-Hodgkin lymphoma to apoptosis by various chemotherapeutic drugs.
  • Rituximab in combination with chemotherapy is considered for the treatment of patients with AIDS-associated B-cell non-Hodgkin lymphoma (NHL); however, a subgroup of patients does not respond or develops resistance following initial treatments.
  • These findings offer novel potential therapeutic applications in the reversal of rituximab/drug resistant AIDS-derived B-NHL.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Drug Resistance, Neoplasm / drug effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, B-Cell / drug therapy. NF-kappa B / antagonists & inhibitors

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18949621.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Grant] United States / FIC NIH HHS / TW / D43 TW00013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Boronic Acids; 0 / Cyclohexanones; 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / dehydroxymethylepoxyquinomicin; 4F4X42SYQ6 / Rituximab; 69G8BD63PP / Bortezomib
  •  go-up   go-down


35. Seoane Lestón J, Diz Dios P: Diagnostic clinical aids in oral cancer. Oral Oncol; 2010 Jun;46(6):418-22
MedlinePlus Health Information. consumer health - Oral Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic clinical aids in oral cancer.
  • Conventional oral exploration (visual and palpation examination) constitutes the current gold standard for oral cancer screening, while biopsy and histopathological examination represents the indispensable study for the detection of cases in patients with an identified lesion.
  • There are also a number of techniques that may contribute to the diagnosis of oral cancer: toluidine blue test has been used as a diagnostic aid for the detection of oral cancer over decades.
  • In the near future, immunological and biochemical alterations in the serum (e.g., circulating immune complexes, carcinoembryonic antigen, squamous cell carcinoma associated antigen, inhibitor of apoptosis, cytokeratin fragments, and annexin A1) as well as specific saliva analysis (e.g., cancer related cytokines, metalloproteinases, epithelial tumour markers, DNA promoter hypermethylation, and saliva micro-RNA) may become important tools for the detection of oral cancer.
  • [MeSH-minor] Female. Humans. Male. Mouth Mucosa / pathology. Neoplasm Staging. Physical Examination. Saliva / chemistry. Sensitivity and Specificity

  • Genetic Alliance. consumer health - AIDS-HIV.
  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20371204.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents; 15XUH0X66N / Tolonium Chloride
  •  go-up   go-down


36. Lim ST, Tupule A, Espina BM, Levine AM: Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma. Cancer; 2005 Jan 15;103(2):417-21
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Weekly docetaxel is safe and effective in the treatment of advanced-stage acquired immunodeficiency syndrome-related Kaposi sarcoma.
  • BACKGROUND: Intravenous paclitaxel, 100 mg/m(2), given over 3 hours every 2 weeks is associated with a response rate of 59% in patients with recurrent or refractory acquired immunodeficiency syndrome (AIDS)-related Kaposi sarcoma (KS).
  • CONCLUSIONS: Weekly docetaxel is safe, with reasonable antitumor activity in patients with advanced-stage, recurrent, or refractory AIDS-related KS.
  • [MeSH-minor] Adult. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Risk Assessment. Survival Analysis. Treatment Outcome


37. Sharma R, Iyer M: Bowen's disease of the nipple in a young man with AIDS: a case report. Clin Breast Cancer; 2009 Feb;9(1):53-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bowen's disease of the nipple in a young man with AIDS: a case report.
  • Bowen's disease, or squamous cell carcinoma in situ (SCCIS) of the skin, is a malignant neoplasm restricted to the epidermis, without evidence of dermal invasion.
  • With the advent of highly active antiretroviral treatment, chronic non-HIV related conditions have become more important, male breast cancer being one of them.


38. Salama ME, Parham DM, Perkins SL, Bahler DW, Ellison DA: Fatal non-transplant-related epstein-barr virus-associated atypical lymphoid proliferations in infants and children: a clinicopathologic study. Pediatr Dev Pathol; 2008 Nov-Dec;11(6):443-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fatal non-transplant-related epstein-barr virus-associated atypical lymphoid proliferations in infants and children: a clinicopathologic study.
  • Most Epstein-Barr virus (EBV)-related infections in infants and children are asymptomatic or self-limited mild viral illnesses, but rare cases of a rapidly fatal disorder have been described.
  • Failure of the cellular response to control EBV-related lymphoid proliferation leads to severe disease with multiple complications, including a fatal outcome or development of an EBV-driven, clonal lymphoid neoplasm.
  • In this report we characterize 3 cases of fatal, nontransplant, or immunodeficiency-related EBV infection in very young children with immunophenotypic and molecular evidence of B/natural killer (NK)-T cell clonal expansion.
  • A high index of suspicion, coupled with appropriate serologic and molecular testing, aids in early recognition and diagnosis of these lymphoproliferative processes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18473605.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 135844-68-7 / RPL22 protein, human
  •  go-up   go-down


39. Capalbo G, Müller-Kuller T, Dietrich U, Hoelzer D, Ottmann OG, Scheuring UJ: Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression. Retrovirology; 2010;7:26
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of HIV-1 replication by small interfering RNAs directed against glioma pathogenesis related protein (GliPR) expression.
  • BACKGROUND: Previously, we showed that glioma pathogenesis related protein (GliPR) is induced in CEM T cells upon HIV-1 infection in vitro.
  • [MeSH-major] Antiviral Agents / pharmacology. Biological Products / pharmacology. HIV-1 / physiology. Neoplasm Proteins / antagonists & inhibitors. Nerve Tissue Proteins / antagonists & inhibitors. RNA, Small Interfering / pharmacology. Virus Replication

  • Genetic Alliance. consumer health - Glioma.
  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2000 Jan 5;266(1):8-16 [10612655.001]
  • [Cites] Exp Hematol. 2000 Jan;28(1):65-76 [10658678.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 1;97(16):8849-55 [10922045.001]
  • [Cites] J Biol Chem. 2001 Feb 2;276(5):3254-61 [11024024.001]
  • [Cites] J Biol Chem. 2002 Jan 25;277(4):2396-405 [11704662.001]
  • [Cites] Mol Cell Biol. 2002 May;22(10):3345-57 [11971968.001]
  • [Cites] Nat Med. 2002 Jul;8(7):681-6 [12042777.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9380-5 [12089333.001]
  • [Cites] BMC Biochem. 2002 Jun 10;3:14 [12069692.001]
  • [Cites] Blood. 2003 Jan 1;101(1):85-90 [12393581.001]
  • [Cites] Hum Gene Ther. 2003 Jan 20;14(2):91-101 [12614561.001]
  • [Cites] Immunol Res. 2003;27(2-3):247-60 [12857972.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31105-10 [12759345.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35211-9 [12842892.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Feb 20;314(4):1126-32 [14751250.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):969-76 [14871827.001]
  • [Cites] AIDS. 2004 Mar 5;18(4):587-96 [15090763.001]
  • [Cites] J Mol Biol. 2004 May 21;339(1):173-83 [15123429.001]
  • [Cites] J Virol. 2004 Sep;78(17):9458-73 [15308739.001]
  • [Cites] EMBO J. 1990 Apr;9(4):1165-70 [2182321.001]
  • [Cites] J Virol. 1992 May;66(5):2814-20 [1560526.001]
  • [Cites] J Virol Methods. 1992 Sep;39(1-2):15-26 [1430060.001]
  • [Cites] J Biol Chem. 1995 Mar 3;270(9):4792-6 [7876252.001]
  • [Cites] Gene. 1995 Jun 14;159(1):131-5 [7607567.001]
  • [Cites] Mol Reprod Dev. 1996 Jun;44(2):221-9 [9115720.001]
  • [Cites] Gene. 1996 Nov 21;180(1-2):125-30 [8973356.001]
  • [Cites] FEBS Lett. 1997 Mar 17;405(1):68-72 [9094426.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 3;95(5):2262-6 [9482873.001]
  • [Cites] AIDS. 1998 Apr 16;12(6):563-70 [9583595.001]
  • [Cites] AIDS. 1999 Feb 4;13(2):167-75 [10202822.001]
  • [Cites] J Immunol. 2004 Dec 1;173(11):6858-63 [15557180.001]
  • [Cites] Annu Rev Genet. 2004;38:61-85 [15568972.001]
  • [Cites] Curr HIV Res. 2005 Jan;3(1):87-94 [15638726.001]
  • [Cites] Jpn J Infect Dis. 2005 Jun;58(3):125-30 [15973003.001]
  • [Cites] Cell Death Differ. 2005 Aug;12 Suppl 1:916-23 [15719026.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10200-5 [16009940.001]
  • [Cites] Retrovirology. 2005;2:63 [16232320.001]
  • [Cites] Mol Cells. 2006 Feb 28;21(1):7-20 [16511342.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4139-48 [16618735.001]
  • [Cites] Cancer Gene Ther. 2006 Jul;13(7):658-63 [16485011.001]
  • [Cites] J Leukoc Biol. 2006 Nov;80(5):973-83 [16908514.001]
  • [Cites] Annu Rev Phytopathol. 2006;44:135-62 [16602946.001]
  • [Cites] Intervirology. 2007;50(3):224-8 [17356300.001]
  • [Cites] Retrovirology. 2007;4:41 [17565699.001]
  • [Cites] Retrovirology. 2007;4:52 [17651505.001]
  • [Cites] Neoplasia. 2007 Nov;9(11):970-8 [18030365.001]
  • [Cites] Science. 2008 Feb 15;319(5865):921-6 [18187620.001]
  • [Cites] Retrovirology. 2008;5:8 [18226242.001]
  • [Cites] Retrovirology. 2008;5:19 [18261236.001]
  • [Cites] Mol Immunol. 2008 May;45(10):2905-19 [18342939.001]
  • [Cites] J Virol. 2000 Apr;74(7):3264-72 [10708443.001]
  • (PMID = 20356381.001).
  • [ISSN] 1742-4690
  • [Journal-full-title] Retrovirology
  • [ISO-abbreviation] Retrovirology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Biological Products; 0 / GLIPR1 protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC2859388
  •  go-up   go-down


40. Handisurya A, Rieger A, Bankier A, Koller A, Salat A, Stingl G, Kirnbauer R: Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy. Br J Dermatol; 2007 Oct;157(4):788-94
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus type 26 infection causing multiple invasive squamous cell carcinomas of the fingernails in an AIDS patient under highly active antiretroviral therapy.
  • Classification of HPV 26 as high- or intermediate-risk type has been uncertain, due to its rare presence in cervical cancer.
  • [MeSH-major] AIDS-Related Opportunistic Infections / complications. Alphapapillomavirus / classification. Carcinoma, Squamous Cell / virology. Nails. Papillomavirus Infections / complications. Skin Neoplasms / virology
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Disease Progression. Fingers / diagnostic imaging. Fingers / pathology. Humans. Male. Neoplasm Invasiveness. Radiography

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - HPV.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virology. 2004 Jun 20;324(1):17-27 [15183049.001]
  • [Cites] J Invest Dermatol. 2004 Aug;123(2):388-94 [15245440.001]
  • [Cites] J Invest Dermatol. 1984 Apr;82(4):362-6 [6323588.001]
  • [Cites] J Virol. 1986 Feb;57(2):688-92 [3003400.001]
  • [Cites] Laryngoscope. 1993 Mar;103(3):253-7 [8382761.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Jan;20(1):38-41 [8288806.001]
  • [Cites] Br J Dermatol. 1994 Aug;131(2):226-30 [7917987.001]
  • [Cites] J Am Acad Dermatol. 1996 Jun;34(6):1080-2 [8647978.001]
  • [Cites] Dermatol Surg. 2005 Jul;31(7 Pt 1):784-6 [16029708.001]
  • [Cites] Semin Cancer Biol. 1999 Dec;9(6):397-403 [10712886.001]
  • [Cites] Dermatol Surg. 2001 Mar;27(3):246-51 [11277891.001]
  • [Cites] J Am Acad Dermatol. 2005 Oct;53(4):737-9 [16198810.001]
  • [Cites] J Clin Microbiol. 2002 Mar;40(3):1088-90 [11880448.001]
  • [Cites] Arch Dermatol. 2000 Jun;136(6):707-10 [10871930.001]
  • [Cites] J Clin Immunol. 2004 Jul;24(4):379-88 [15163894.001]
  • [Cites] Br J Dermatol. 2004 May;150(5):949-57 [15149508.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Oct 1;34(2):140-54 [14526203.001]
  • [Cites] Dermatol Surg. 2003 Sep;29(9):984-6 [12930348.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1570-7 [12771924.001]
  • [Cites] J Am Acad Dermatol. 2003 Mar;48(3):385-93 [12637918.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [ErratumIn] Br J Dermatol. 2007 Dec;157(6):1304
  • (PMID = 17634082.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / P 18990
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ EMS55131; NLM/ PMC3935457
  •  go-up   go-down


41. Toure G, Roucayrol AM, Meningaud JP, Bertrand JC: Plasmablastic lymphoma: a case report. Quintessence Int; 2007 Feb;38(2):161-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Unfortunately, as for other high-grade lymphomas in patients with acquired immunodeficiency syndrome (AIDS), the prognosis is poor.
  • The case of a heterosexual 42-year-old man referred for a right hemifacial neoplasm is reported.
  • [MeSH-major] HIV-1. Lymphoma, AIDS-Related / pathology. Maxillary Neoplasms / pathology

  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17263156.001).
  • [ISSN] 0033-6572
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Heise W: GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol; 2010 Feb;24(1):57-69
MedlinePlus Health Information. consumer health - Organ Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the introduction of highly active antiretroviral therapy (HAART) in the therapeutic concept in AIDS, a decrease of AIDS-related GI lymphoma was noted with improved survival rates and prognosis of lymphoma.
  • [MeSH-major] Gastrointestinal Neoplasms / immunology. HIV Infections / immunology. Immunocompromised Host. Immunosuppressive Agents / adverse effects. Lymphoma / immunology. Lymphoma, AIDS-Related / immunology. Organ Transplantation
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Endoscopy, Gastrointestinal. Humans. Immunotherapy / methods. Neoplasm Staging. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20206109.001).
  • [ISSN] 1532-1916
  • [Journal-full-title] Best practice & research. Clinical gastroenterology
  • [ISO-abbreviation] Best Pract Res Clin Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 84
  •  go-up   go-down


43. Tanaka PY, Calore EE: P-glycoprotein expression in non-Hodgkin's lymphomas of human immunodeficiency virus infected patients. Pathol Res Pract; 2007;203(1):1-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Multidrug resistance (MDR) is a challenge in cancer treatment.
  • AIDS-related lymphomas have aggressive behavior, and although a complete response could be achieved, relapse is not uncommon.
  • Our results show that P-gp is expressed before treatment of non-Hodgkin's lymphoma of HIV patients, and is related to poor response to treatment and overall survival.
  • [MeSH-major] Acquired Immunodeficiency Syndrome. Lymphoma, AIDS-Related / metabolism. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Anti-HIV Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiretroviral Therapy, Highly Active / mortality. Biomarkers, Tumor / metabolism. Cell Count. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Retrospective Studies. Survival Rate. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pathol Res Pract. 2007;203(10):763
  • (PMID = 17157997.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Biomarkers, Tumor; 0 / P-Glycoprotein; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


44. Boué F, Gabarre J, Gisselbrecht C, Reynes J, Cheret A, Bonnet F, Billaud E, Raphael M, Lancar R, Costagliola D: Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol; 2006 Sep 1;24(25):4123-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the safety and efficacy of rituximab adjunction to the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen in patients with newly diagnosed AIDS-related non-Hodgkin's lymphoma.
  • PATIENTS AND METHODS: HIV-seropositive patients with high-grade lymphoma of B-cell origin were eligible if they had no more than one of the following characteristics: CD4 cell count less than 100/microL, prior AIDS, or performance status less than 2.
  • CONCLUSION: Rituximab adjunction to CHOP produced a CR rate of 77% and a 2-year survival rate of 75% in patients with AIDS-related non-Hodgkin's lymphoma, without increasing the risk of life-threatening infections.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Feasibility Studies. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prognosis. Risk Factors. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e6 [17308260.001]
  • [CommentIn] J Clin Oncol. 2007 Feb 20;25(6):e7 [17308261.001]
  • (PMID = 16896005.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


45. Osorio S G, Montenegro U C: [Lymphomas and HIV infection in a reference hospital of Santiago, Chile: 1990-2002: report of 14 cases and review]. Rev Chilena Infectol; 2007 Apr;24(2):117-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten patients were classified under stage C3 of AIDS CDC criteria, the mean CD4 count was 139 cells/mm3 and mean CV was 5,32 log.
  • The low incidence of lymphoma and AIDS association and the high frequency of lymphomas with localized or generalized lymphonodes in this series are remarkable.
  • [MeSH-major] Lymphoma, AIDS-Related. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. CD4 Lymphocyte Count. Chile / epidemiology. Female. Hodgkin Disease / diagnosis. Hodgkin Disease / drug therapy. Hodgkin Disease / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Viral Load

  • Genetic Alliance. consumer health - HIV.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17453069.001).
  • [ISSN] 0716-1018
  • [Journal-full-title] Revista chilena de infectología : órgano oficial de la Sociedad Chilena de Infectología
  • [ISO-abbreviation] Rev Chilena Infectol
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Chile
  • [Number-of-references] 30
  •  go-up   go-down


46. Vega F, Chang CC, Medeiros LJ, Udden MM, Cho-Vega JH, Lau CC, Finch CJ, Vilchez RA, McGregor D, Jorgensen JL: Plasmablastic lymphomas and plasmablastic plasma cell myelomas have nearly identical immunophenotypic profiles. Mod Pathol; 2005 Jun;18(6):806-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Plasmablastic lymphoma is an aggressive neoplasm that shares many cytomorphologic and immunophenotypic features with plasmablastic plasma cell myeloma.
  • To characterize the relationship between plasmablastic lymphoma and plasmablastic plasma cell myeloma, we performed immunohistochemistry using a large panel of B-cell and plasma cell markers on nine cases of plasmablastic lymphoma and seven cases of plasmablastic plasma cell myeloma with and without HIV/AIDS.
  • No evidence of HHV-8 infection was detected in either neoplasm.
  • In conclusion, most cases of AIDS-related plasmablastic lymphoma have an immunophenotype and tumor suppressor gene expression profile virtually identical to plasmablastic plasma cell myeloma, and unlike diffuse large B-cell lymphoma.
  • [MeSH-minor] Adult. Aged. Antigens, CD / analysis. DNA, Viral / genetics. DNA-Binding Proteins / analysis. Epstein-Barr Virus Infections / immunology. Epstein-Barr Virus Infections / pathology. Epstein-Barr Virus Infections / virology. Female. Herpesvirus 4, Human / genetics. Herpesvirus 8, Human / genetics. Humans. Immunohistochemistry. In Situ Hybridization. Ki-67 Antigen / analysis. Lymphoma, AIDS-Related / immunology. Lymphoma, AIDS-Related / pathology. Lymphoma, AIDS-Related / virology. Male. Middle Aged. Polymerase Chain Reaction. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis. Proto-Oncogene Proteins c-bcl-6. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Mod Pathol. 2005 Jun;18(6):873. Medeiros, Leonard J [corrected to Medeiros, L Jeffrey]
  • (PMID = 15578069.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / DNA, Viral; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Proto-Oncogene Proteins c-bcl-6; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


47. Boulanger E, Meignin V, Afonso PV, Duprez R, Oksenhendler E, Agbalika F, Gessain A: Extracavitary tumor after primary effusion lymphoma: relapse or second distinct lymphoma? Haematologica; 2007 Sep;92(9):1275-6
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HHV-8-associated solid lymphomas which develop in extracavitary sites during the course of primary effusion lymphoma (PEL) could represent the relapse of original PEL tumors in different anatomical sites, or newly occurring distinct HHV-8-associated lymphomas, such as multicentric Castleman disease-related microlymphomas.
  • [MeSH-major] Herpesviridae Infections / complications. Herpesvirus 8, Human / isolation & purification. Lymphoma / complications. Lymphoma, AIDS-Related / complications. Neoplasm Recurrence, Local / complications. Pleural Effusion, Malignant / complications

  • Genetic Alliance. consumer health - Primary effusion lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17768127.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  •  go-up   go-down


48. Tanaka PY, Pessoa VP Jr, Pracchia LF, Buccheri V, Chamone DA, Calore EE: Hodgkin lymphoma among patients infected with HIV in post-HAART era. Clin Lymphoma Myeloma; 2007 Mar;7(5):364-8
Hazardous Substances Data Bank. VINBLASTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hodgkin lymphoma is considered a common type of non-AIDS defining tumor among patients infected with HIV, commonly presenting as a widespread disease and with different pathologic features compared with Hodgkin lymphoma in the general population.
  • On univariate analysis, only CD4 cell count at diagnosis was significantly related to survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. HIV Infections / drug therapy. Hodgkin Disease / drug therapy. Lymphoma, AIDS-Related / drug therapy
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / statistics & numerical data. Bleomycin / administration & dosage. Brazil / epidemiology. Comorbidity. Dacarbazine / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Male. Mechlorethamine / administration & dosage. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Procarbazine / administration & dosage. Remission Induction. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome. Vinblastine / administration & dosage. Vincristine / administration & dosage


49. Loya AC, Prayaga AK, Sundaram C, Shantharam V, Kumar A: Cytologic diagnosis of pancreatic tuberculosis in immunocompetent and immunocompromised patients: a report of 2 cases. Acta Cytol; 2005 Jan-Feb;49(1):97-100
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pancreatic involvement by tuberculosis in immunocompromised states, such as AIDS, and isolated involvement in immunocompetent patients require a high index of suspicion.
  • It resolves the diagnostic dilemma and thus avoids major surgery for a clinically diagnosed neoplasm.
  • [MeSH-minor] AIDS-Related Opportunistic Infections. Adult. Biopsy, Fine-Needle. Carcinoma / diagnosis. Diabetes Mellitus / physiopathology. Diagnosis, Differential. Fatal Outcome. HIV Seropositivity. Humans. Immunocompromised Host. Lymphatic Diseases / pathology. Lymphoma, Non-Hodgkin / diagnosis. Male. Middle Aged. Pancreas / pathology. Pancreas / radiography. Pancreatic Neoplasms / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Pancreatic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15717764.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Franzetti F, Grassini A, Piazza M, Degl'innocenti M, Bandera A, Gazzola L, Marchetti G, Gori A: Nosocomial bacterial pneumonia in HIV-infected patients: risk factors for adverse outcome and implications for rational empiric antibiotic therapy. Infection; 2006 Feb;34(1):9-16
MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nosocomial bacterial pneumonia (NBP) was once considered a common cause of morbidity and mortality among advanced AIDS patients.
  • Non-statistically significant factors associated with shorter survival were: CD4(+) count < 10 cells/microl, concomitant lung neoplasm, and complicated roentgenographic picture.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / drug therapy. AIDS-Related Opportunistic Infections / epidemiology. AIDS-Related Opportunistic Infections / microbiology. AIDS-Related Opportunistic Infections / mortality. Adult. Antiretroviral Therapy, Highly Active. Female. Humans. Incidence. Male. Methicillin Resistance. Microbial Sensitivity Tests. Middle Aged. Pseudomonas aeruginosa / drug effects. Pseudomonas aeruginosa / isolation & purification. Risk Factors. Staphylococcus aureus / drug effects. Staphylococcus aureus / isolation & purification. Streptococcus pneumoniae / drug effects. Streptococcus pneumoniae / isolation & purification. Survival Analysis

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16501896.001).
  • [ISSN] 0300-8126
  • [Journal-full-title] Infection
  • [ISO-abbreviation] Infection
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


51. Pyakurel P, Montag U, Castaños-Vélez E, Kaaya E, Christensson B, Tönnies H, Biberfeld P, Heiden T: CGH of microdissected Kaposi's sarcoma lesions reveals recurrent loss of chromosome Y in early and additional chromosomal changes in late tumour stages. AIDS; 2006 Sep 11;20(14):1805-12
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: We analysed 27 KS, early and late, AIDS related (AKS) and endemic (EKS) by laser microdissection, global DNA amplification and comparative genomic hybridization (CGH).
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / genetics. Chromosomes, Human, X / genetics. DNA, Neoplasm / genetics. Female. Herpesvirus 8, Human / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Male. Microdissection / methods. Neoplasm Staging. Nucleic Acid Amplification Techniques / methods

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954721.001).
  • [ISSN] 0269-9370
  • [Journal-full-title] AIDS (London, England)
  • [ISO-abbreviation] AIDS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


52. Hentrich M, Maretta L, Chow KU, Bogner JR, Schürmann D, Neuhoff P, Jäger H, Reichelt D, Vogel M, Ruhnke M, Oette M, Weiss R, Rockstroh J, Arasteh K, Mitrou P: Highly active antiretroviral therapy (HAART) improves survival in HIV-associated Hodgkin's disease: results of a multicenter study. Ann Oncol; 2006 Jun;17(6):914-9
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 66 patients with HIV-HD, 47 (71%) presented with stage III/IV disease and 38 patients (58%) with an AIDS-defining illness.

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565210.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


53. Cantarella G, Risuglia N, Dell'eva R, Lempereur L, Albini A, Pennisi G, Scoto GM, Noonan DN, Bernardini R: TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. Br J Cancer; 2006 May 22;94(10):1428-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour growth is tightly related to new blood vessel formation, tissue remodelling and invasiveness capacity.
  • A number of tissular factors fuel the growth of glioblastoma multiforme, the most aggressive brain neoplasm.
  • In fact, gene array analyses demonstrated that the proapoptotic cytokine tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) inhibited mRNA expression of VEGF, along with those of matrix metalloproteinase-2 (MMP-2), its inhibitor tissue inhibitor of matrix metalloproteinases-2 (TIMP-2), as well as the tumour invasiveness-related gene secreted protein acid rich in cysteine (SPARC) in different human glioblastoma cell lines.
  • Moreover, the expression of MMP-2, its inhibitor TIMP-2 and the tumour invasiveness-related protein SPARC were effectively inhibited by TRAIL in glioblastoma cell lines.
  • [MeSH-minor] Animals. Blotting, Western. Cell Survival. Endothelium, Vascular / drug effects. Enzyme-Linked Immunosorbent Assay. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / drug effects. Humans. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Mice. Mice, Inbred C57BL. Oligonucleotide Array Sequence Analysis. Osteonectin / genetics. Osteonectin / metabolism. RNA, Messenger / metabolism. TNF-Related Apoptosis-Inducing Ligand. Tissue Inhibitor of Metalloproteinase-2 / genetics. Tissue Inhibitor of Metalloproteinase-2 / metabolism. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6270-7 [12414657.001]
  • [Cites] Br J Cancer. 1998;77(1):1-10 [9459138.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):213-26 [12510773.001]
  • [Cites] Circulation. 2003 May 6;107(17):2250-6 [12668516.001]
  • [Cites] Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):495-502 [10571411.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2000 May;278(5):L1045-50 [10781437.001]
  • [Cites] J Cell Biol. 1998 Jun 29;141(7):1659-73 [9647657.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):429-37 [9708803.001]
  • [Cites] EXS. 2005;(94):209-31 [15617481.001]
  • [Cites] Kidney Int. 2005 Feb;67(2):449-57 [15673292.001]
  • [Cites] Apoptosis. 2005 Jan;10(1):233-43 [15711939.001]
  • [Cites] Int J Oncol. 2005 May;26(5):1273-81 [15809718.001]
  • [Cites] J Vasc Res. 2005 Jul-Aug;42(4):337-47 [15985761.001]
  • [Cites] Clin Exp Metastasis. 1999;17(7):555-66 [10845554.001]
  • [Cites] Int J Cancer. 2000 Jul 15;87(2):261-8 [10861485.001]
  • [Cites] Lancet. 2000 Sep 2;356(9232):827-8 [11022932.001]
  • [Cites] Pediatr Neurosurg. 2000 Jul;33(1):49-55 [11025423.001]
  • [Cites] Acta Pharmacol Sin. 2000 Mar;21(3):211-4 [11324417.001]
  • [Cites] Clin Cancer Res. 2001 May;7(5):1362-9 [11350907.001]
  • [Cites] J Cell Physiol. 2001 Nov;189(2):197-206 [11598905.001]
  • [Cites] J Neurooncol. 2001 Jun;53(2):213-35 [11716072.001]
  • [Cites] FASEB J. 2002 Apr;16(6):555-64 [11919158.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7077-91 [12370830.001]
  • [Cites] Nat Med. 2003 Jun;9(6):669-76 [12778165.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48 [12787570.001]
  • [Cites] Cancer Res. 2003 Jul 15;63(14):4181-7 [12874024.001]
  • [Cites] J Immunol. 2003 Aug 1;171(3):1526-33 [12874246.001]
  • [Cites] Lab Invest. 2004 Jan;84(1):8-20 [14631378.001]
  • [Cites] Cancer Treat Res. 2004;117:219-48 [15015563.001]
  • [Cites] Neoplasia. 2004 Jul-Aug;6(4):364-73 [15256058.001]
  • [Cites] Front Biosci. 2004 Sep 1;9:2474-83 [15353300.001]
  • [Cites] Cancer Sci. 2004 Oct;95(10):840-4 [15504253.001]
  • [Cites] J Clin Invest. 1973 Nov;52(11):2745-56 [4355998.001]
  • [Cites] Acta Neuropathol. 1987;72(3):207-13 [3564901.001]
  • [Cites] J Cell Biochem. 1992 Jul;49(3):272-83 [1644864.001]
  • [Cites] Lab Invest. 1992 Oct;67(4):519-28 [1279270.001]
  • [Cites] AIDS. 1994 Sep;8(9):1237-44 [7528513.001]
  • [Cites] Int J Cancer. 1995 Mar 29;61(1):121-9 [7705924.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):298-307 [7616276.001]
  • [Cites] Nat Med. 1995 Jan;1(1):27-31 [7584949.001]
  • [Cites] J Biol Chem. 1996 Jun 21;271(25):15074-83 [8663054.001]
  • [Cites] EXS. 1997;79:47-64 [9002220.001]
  • [Cites] Endocr Rev. 1997 Feb;18(1):4-25 [9034784.001]
  • [Cites] Nature. 1997 Apr 17;386(6626):671-4 [9109485.001]
  • [Cites] J Urol. 1997 Jun;157(6):2329-33 [9146665.001]
  • [Cites] Science. 1997 Aug 8;277(5327):818-21 [9242611.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6B):4163-72 [9428350.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:e261-9 [12456313.001]
  • (PMID = 16622457.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Apoptosis Regulatory Proteins; 0 / Membrane Glycoproteins; 0 / Osteonectin; 0 / RNA, Messenger; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFSF10 protein, human; 0 / Tnfsf10 protein, mouse; 0 / Tumor Necrosis Factor-alpha; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.24 / Matrix Metalloproteinase 2
  • [Other-IDs] NLM/ PMC2361261
  •  go-up   go-down


54. Ribera JM, Oriol A, Morgades M, González-Barca E, Miralles P, López-Guillermo A, Gardella S, López A, Abella E, García M, PETHEMA, GELTAMO, GELCAB and GESIDA Groups: Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol; 2008 Feb;140(4):411-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunochemotherapy with cyclophosphamide, adriamycin, vincristine, prednisone and rituximab (R-CHOP) is the standard treatment in non-immunosuppressed patients with diffuse large B-cell lymphoma (DLBCL), but its adequacy has not been definitively established in patients with human immunodeficiency virus (HIV)-related lymphoma.
  • This phase II trial aimed to evaluate the safety and efficacy of six cycles of R-CHOP in patients with HIV-related DLBCL and to determine whether response to highly active antiretroviral therapy (HAART) had prognostic impact.
  • In HIV-related DLBCL R-CHOP is feasible, safe and effective.
  • The prognosis depends on lymphoma-related parameters and on the response to HAART.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, AIDS-Related / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / adverse effects. Antibodies, Monoclonal, Murine-Derived. Antiretroviral Therapy, Highly Active. CD4 Lymphocyte Count. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Prognosis. Rituximab. Survival Analysis. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects. Viral Load

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162120.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


55. Salemi M, Lamers SL, Huysentruyt LC, Galligan D, Gray RR, Morris A, McGrath MS: Distinct patterns of HIV-1 evolution within metastatic tissues in patients with non-Hodgkins lymphoma. PLoS One; 2009 Dec 03;4(12):e8153
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite highly active antiretroviral therapy (HAART), AIDS related lymphoma (ARL) occurs at a significantly higher rate in patients infected with the Human Immunodeficiency Virus (HIV) than in the general population.
  • We sequenced HIV-1 envelope gp120 clones obtained post mortem from several tumor and non-tumor tissues of two patients who died with AIDS-related Non-Hodgkin's lymphoma (ARL-NH).

  • Genetic Alliance. consumer health - HIV.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2006 Jan 1;107(1):13-20 [16099881.001]
  • [Cites] Nature. 2005 Dec 8;438(7069):820-7 [16341007.001]
  • [Cites] Genetics. 2006 Apr;172(4):2665-81 [16489234.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Clin Lymphoma Myeloma. 2007 Jan;7(4):272-9 [17324334.001]
  • [Cites] PLoS Comput Biol. 2007 Feb 16;3(2):e29 [17305421.001]
  • [Cites] PLoS One. 2007;2(9):e950 [17895991.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1365-72 [18042692.001]
  • [Cites] Leuk Lymphoma. 2007 Dec;48(12):2403-11 [18067016.001]
  • [Cites] Retrovirology. 2007;4:87 [18053211.001]
  • [Cites] BMC Evol Biol. 2007;7:214 [17996036.001]
  • [Cites] Mol Phylogenet Evol. 2008 Nov;49(2):618-28 [18801446.001]
  • [Cites] Nat Rev Cancer. 2009 Apr;9(4):285-93 [19308068.001]
  • [Cites] PLoS One. 2009;4(3):e5065 [19333384.001]
  • [Cites] Genetics. 2000 Jul;155(3):1429-37 [10880500.001]
  • [Cites] AIDS. 2000 Dec 22;14(18):2937-9 [11153675.001]
  • [Cites] Mol Biol Evol. 2001 Jun;18(6):1001-13 [11371589.001]
  • [Cites] Science. 2001 Dec 14;294(5550):2310-4 [11743192.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5536-42 [12359765.001]
  • [Cites] J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20 [12843741.001]
  • [Cites] Syst Biol. 2003 Oct;52(5):696-704 [14530136.001]
  • [Cites] Science. 2004 Jan 16;303(5656):327-32 [14726583.001]
  • [Cites] Bioinformatics. 2004 Feb 12;20(3):436-8 [14960476.001]
  • [Cites] Genetics. 1989 Nov;123(3):603-13 [2599370.001]
  • [Cites] Lancet. 1991 Apr 6;337(8745):805-9 [1672911.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2069-72 [8174106.001]
  • [Cites] AIDS. 1994 Aug;8(8):1025-49 [7986399.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Apr 1;8(4):379-85 [7882103.001]
  • [Cites] Comput Appl Biosci. 1997 Oct;13(5):555-6 [9367129.001]
  • [Cites] Nucleic Acids Res. 1997 Dec 15;25(24):4876-82 [9396791.001]
  • [Cites] Immunol Rev. 1998 Apr;162:293-8 [9602372.001]
  • [Cites] Am J Epidemiol. 1999 Aug 15;150(4):375-89 [10453814.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] Mol Biol Evol. 2005 May;22(5):1185-92 [15703244.001]
  • [Cites] J Virol. 2005 Sep;79(17):11343-52 [16103186.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):605-12 [16423985.001]
  • (PMID = 19997510.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA096230; United States / NCI NIH HHS / CA / U01 CA096230-06; United States / NIAID NIH HHS / AI / R01 AI065265; United States / NINDS NIH HHS / NS / NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA009126; United States / NINDS NIH HHS / NS / R01 NS063897-01A2; United States / NCI NIH HHS / CA / U01 CA066529-14; United States / NINDS NIH HHS / NS / R01 NS063897; United States / NCI NIH HHS / CA / T32 CA09126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HIV Core Protein p24; 0 / HIV Envelope Protein gp120
  • [Other-IDs] NLM/ PMC2780293
  •  go-up   go-down


56. Mbulaiteye SM, Anderson WF, Bhatia K, Rosenberg PS, Linet MS, Devesa SS: Trimodal age-specific incidence patterns for Burkitt lymphoma in the United States, 1973-2005. Int J Cancer; 2010 Apr 1;126(7):1732-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Burkitt lymphoma (BL) is a unique B-cell non-Hodgkin lymphoma with 3 established clinical-epidemiological variants: endemic, sporadic and AIDS-related BL.
  • Therefore, we examined population-based BL incidence patterns in the United States to determine age-related risk.
  • The tri/bimodal incidence pattern was present in sensitivity analyses excluding registries with many HIV/AIDS cases and in period-specific, cohort-specific analyses.
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Child. Child, Preschool. Cross-Sectional Studies. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Staging. Prognosis. Risk Factors. SEER Program. Survival Rate. Time Factors. United States / epidemiology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 UICC.
  • [Cites] Am J Epidemiol. 1995 Feb 15;141(4):300-4 [7840107.001]
  • [Cites] Biometrics. 1995 Sep;51(3):874-87 [7548706.001]
  • [Cites] Am J Epidemiol. 1996 Jan 1;143(1):85-91 [8533751.001]
  • [Cites] Blood. 1999 Feb 1;93(3):1124 [10025990.001]
  • [Cites] Blood. 1999 Jan 15;93(2):758 [10215347.001]
  • [Cites] Cancer. 1957 Sep-Oct;10(5):1045-54 [13472655.001]
  • [Cites] Haematologica. 2008 Sep;93(9):1327-34 [18698080.001]
  • [Cites] Ann Oncol. 2000;11 Suppl 1:3-10 [10707771.001]
  • [Cites] Ann Intern Med. 1969 Apr;70(4):817-32 [4306129.001]
  • [Cites] Br J Prev Soc Med. 1971 Nov;25(4):242-4 [5160433.001]
  • [Cites] Nature. 1972 May 5;237(5349):33-4 [4113130.001]
  • [Cites] Eur J Cancer. 1972 Jun;8(3):305-8 [4677829.001]
  • [Cites] N Engl J Med. 1981 Sep 24;305(13):735-45 [7022215.001]
  • [Cites] Lancet. 1982 Sep 18;2(8299):631-3 [6125777.001]
  • [Cites] Biometrics. 1983 Jun;39(2):311-24 [6626659.001]
  • [Cites] Stat Med. 1987 Jun;6(4):449-67 [3629047.001]
  • [Cites] Stat Med. 1987 Jun;6(4):469-81 [3629048.001]
  • [Cites] Br J Surg. 1958 Nov;46(197):218-23 [13628987.001]
  • [Cites] Br J Cancer. 1963 Mar;17:50-5 [14001942.001]
  • [Cites] J Pathol. 2008 Dec;216(4):440-50 [18802929.001]
  • [Cites] Nat Rev Microbiol. 2008 Dec;6(12):913-24 [19008891.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2008;:341-8 [19074108.001]
  • [Cites] J Natl Cancer Inst. 2008 Dec 17;100(24):1804-14 [19066264.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):366-70 [19434731.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Aug;18(8):2256-61 [19622723.001]
  • [Cites] MMWR Morb Mortal Wkly Rep. 2006 Jun 2;55(21):589-92 [16741494.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2419-30 [16760442.001]
  • [Cites] AIDS. 2006 Aug 1;20(12):1645-54 [16868446.001]
  • [Cites] MMWR Suppl. 1987 Dec 25;36(7):1S-20S [2826984.001]
  • [Cites] Annu Rev Public Health. 1991;12:425-57 [2049144.001]
  • [Cites] Am J Epidemiol. 1987 Oct;126(4):578-86 [3631049.001]
  • (PMID = 19810101.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z01 CP010176-07; United States / Intramural NIH HHS / / ZIA CP010176-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS146203; NLM/ PMC2818154
  •  go-up   go-down


57. Catrina SB, Lewitt M, Massambu C, Dricu A, Grünler J, Axelson M, Biberfeld P, Brismar K: Insulin-like growth factor-I receptor activity is essential for Kaposi's sarcoma growth and survival. Br J Cancer; 2005 Apr 25;92(8):1467-74
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a highly vascular tumour and is the most common neoplasm associated with human immunodeficiency virus (HIV-1) infection.
  • The IGF-I receptors (IGF-IR) were identified by immunohistochemistry in biopsies taken from patients with different AIDS/HIV-related KS stages and on KSIMM cells (an established KS-derived cell line).

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • HIV InSite. treatment guidelines - Human Herpesvirus-8 .
  • Hazardous Substances Data Bank. PODOFILOX .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AIDS. 1999 Dec 24;13(18):2563-70 [10630526.001]
  • [Cites] J Invest Dermatol. 1999 Dec;113(6):1047-53 [10594750.001]
  • [Cites] Endocr Rev. 2000 Jun;21(3):215-44 [10857553.001]
  • [Cites] Med Oncol. 2000 Nov;17(4):325-32 [11114713.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5804-8 [11331770.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):373-82 [12044013.001]
  • [Cites] Cancer Cell. 2002 Mar;1(2):117-23 [12086869.001]
  • [Cites] Cell Growth Differ. 2002 Aug;13(8):387-95 [12193477.001]
  • [Cites] Ann Rheum Dis. 2002 Oct;61(10):934-6 [12228167.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):39684-95 [12138094.001]
  • [Cites] Endocrine. 2002 Dec;19(3):239-48 [12624423.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):231-9 [15050915.001]
  • [Cites] Mol Cancer Ther. 2004 May;3(5):527-35 [15141010.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Feb;83(3):664-8 [3003744.001]
  • [Cites] Acta Endocrinol (Copenh). 1991 Jun;124(6):620-9 [2068892.001]
  • [Cites] Am J Pathol. 1991 Dec;139(6):1251-8 [1750501.001]
  • [Cites] Endocrinology. 1992 Aug;131(2):890-5 [1379166.001]
  • [Cites] J Endocrinol. 1992 Aug;134(2):169-76 [1383373.001]
  • [Cites] J Immunol Methods. 1996 Jan 16;189(1):117-27 [8576573.001]
  • [Cites] Cancer Res. 1996 Apr 15;56(8):1874-9 [8620507.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Feb 4;94(3):979-84 [9023368.001]
  • [Cites] AIDS. 1997 May;11(6):713-21 [9143602.001]
  • [Cites] Science. 1997 May 23;276(5316):1268-72 [9157888.001]
  • [Cites] Cytokine Growth Factor Rev. 1998 Mar;9(1):63-83 [9720757.001]
  • [Cites] FASEB J. 1999 Apr;13(6):647-55 [10094925.001]
  • [Cites] Life Sci. 1999;65(10):1047-57 [10499872.001]
  • [Cites] Cancer Lett. 2003 Jun 10;195(2):127-37 [12767520.001]
  • [Cites] Cancer Res. 2003 Aug 1;63(15):4384-8 [12907608.001]
  • [Cites] Oncogene. 2003 Sep 29;22(42):6589-97 [14528284.001]
  • [Cites] Cancer Res. 2004 Jan 1;64(1):236-42 [14729630.001]
  • [Cites] J Biol Chem. 2004 Feb 6;279(6):4136-43 [14627715.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):201-2 [15050909.001]
  • [Cites] Cancer Cell. 2004 Mar;5(3):221-30 [15050914.001]
  • [Cites] AIDS. 1999 Oct 22;13(15):2105-11 [10546864.001]
  • [Cites] Nat Med. 1999 Dec;5(12):1390-5 [10581081.001]
  • [Cites] Oncologist. 2000;5 Suppl 1:28-31 [10804088.001]
  • (PMID = 15812560.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Somatomedins; 0 / Vascular Endothelial Growth Factor A; 0F35AOI227 / picropodophyllin; EC 2.7.10.1 / Receptor, IGF Type 1; L36H50F353 / Podophyllotoxin
  • [Other-IDs] NLM/ PMC2362008
  •  go-up   go-down


58. Volkow P, Zinser JW, Correa-Rotter R: Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol; 2007;8:6
Hazardous Substances Data Bank. SIROLIMUS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Imatinib is a tyrosine-kinase inhibitor; for which there is limited information regarding its effects on AIDS Kaposi's sarcoma and none in patients with transplant-associated Kaposi's sarcoma.
  • Sirolimus, an immunosuppressive drug used for kidney transplant, exhibits antiangiogenic activity related to impaired production of VEGF (vascular endothelial growth factor), clinical benefit has been reported in Kaposi's sarcoma associated with renal graft.
  • CASE PRESENTATION: Here we report a case of an 80 year old male, who developed Kaposi's Sarcoma nine months after receiving a living non-related donor kidney transplant at age 74.
  • [MeSH-minor] Aged, 80 and over. Benzamides. Biopsy, Needle. Dose-Response Relationship, Drug. Drug Administration Schedule. Follow-Up Studies. Humans. Imatinib Mesylate. Immunohistochemistry. Kidney Failure, Chronic / diagnosis. Kidney Failure, Chronic / surgery. Male. Neoplasm Staging. Retreatment. Risk Assessment. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1995 Mar;146(3):727-34 [7887453.001]
  • [Cites] Science. 1994 Dec 16;266(5192):1865-9 [7997879.001]
  • [Cites] Br J Dermatol. 1995 Aug;133(2):332-4 [7547414.001]
  • [Cites] Am J Pathol. 1996 Jun;148(6):1999-2008 [8669484.001]
  • [Cites] J Clin Oncol. 2005 Feb 10;23(5):982-9 [15572730.001]
  • [Cites] N Engl J Med. 2005 Mar 31;352(13):1317-23 [15800227.001]
  • [Cites] Transplant Proc. 2005 Mar;37(2):964-6 [15848592.001]
  • [Cites] Int J STD AIDS. 2006 Sep;17(9):571-8 [16942647.001]
  • [Cites] N Engl J Med. 2000 Apr 6;342(14):1027-38 [10749966.001]
  • [Cites] Transplantation. 2004 Mar 15;77(5):760-2 [15021843.001]
  • [Cites] Cancer. 2004 Jun 15;100(12):2592-7 [15197801.001]
  • [Cites] J Invest Dermatol. 1990 Dec;95(6 Suppl):176S-179S [2258634.001]
  • [Cites] Rev Med Interne. 1990 Jul-Aug;11(4):322-4 [2096440.001]
  • [Cites] Cancer. 1993 Sep 1;72(5):1779-83 [8348508.001]
  • [Cites] J Am Acad Dermatol. 1993 Nov;29(5 Pt 2):890-4 [8408835.001]
  • [Cites] Lancet. 1995 Mar 25;345(8952):759-61 [7891487.001]
  • (PMID = 17386117.001).
  • [ISSN] 1471-2369
  • [Journal-full-title] BMC nephrology
  • [ISO-abbreviation] BMC Nephrol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ PMC1852096
  •  go-up   go-down


59. Ganem D: KSHV infection and the pathogenesis of Kaposi's sarcoma. Annu Rev Pathol; 2006;1:273-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we review the evidence linking KSHV infection to KS risk and discuss current notions of how KSHV gene expression promotes the development of this remarkable neoplasm.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / pathology. AIDS-Related Opportunistic Infections / virology. Gene Expression Regulation, Viral. Humans. Male. Virus Latency

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18039116.001).
  • [ISSN] 1553-4006
  • [Journal-full-title] Annual review of pathology
  • [ISO-abbreviation] Annu Rev Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 158
  •  go-up   go-down


60. Chernilo S, Trujillo S, Kahn M, Paredes M, Echevarría G, Sepúlveda C: [Lung diseases among HIV infected patients admitted to the "Instituto Nacional del Torax" in Santiago, Chile]. Rev Med Chil; 2005 May;133(5):517-24
MedlinePlus Health Information. consumer health - Lung Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Infectious diseases accounted for 87% of the discharges, neoplasm for 5.1%.
  • [MeSH-minor] AIDS-Related Opportunistic Infections / epidemiology. Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / epidemiology. Adult. Aged. Chile / epidemiology. Female. Hospital Mortality. Hospitalization. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970975.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


61. Kreuter A, Rasokat H, Klouche M, Esser S, Bader A, Gambichler T, Altmeyer P, Brockmeyer NH: Liposomal pegylated doxorubicin versus low-dose recombinant interferon Alfa-2a in the treatment of advanced classic Kaposi's sarcoma; retrospective analysis of three German centers. Cancer Invest; 2005;23(8):653-9
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Classic Kaposi's sarcoma (KS) is a rare neoplasm, predominantly occurring in older subjects of Eastern Europe or Mediterranean descent.
  • Several studies reported the effectiveness of pegylated liposomal doxorubicin (PLD) and low-dose recombinant interferon alfa-2a (IFNalpha) in the treatment of AIDS-associated KS.
  • Neutropenia (33 percent) related to PLD was the most common adverse event (4/12).
  • Flu-like symptoms in 3 patients (50 percent) related to IFNalpha were the most common adverse events.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16377582.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Interferon-alpha; 0 / Recombinant Proteins; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 76543-88-9 / interferon alfa-2a; 80168379AG / Doxorubicin
  •  go-up   go-down


62. Rajaram ST, Lobo FD, Achary C: Oropharyngeal plasmablastic lymphoma in a man with human immunodeficiency virus infection: A case report. Ear Nose Throat J; 2010 Dec;89(12):E13
MedlinePlus Health Information. consumer health - HIV/AIDS.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] HIV Infections / diagnosis. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Oropharyngeal Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Deglutition Disorders / diagnosis. Deglutition Disorders / etiology. Disease Progression. Fatal Outcome. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Treatment Refusal

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174265.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Schultz CJ, Bovi J: Current management of primary central nervous system lymphoma. Int J Radiat Oncol Biol Phys; 2010 Mar 1;76(3):666-78
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary central nervous cell lymphoma (PCNSL) is an uncommon neoplasm of the brain, leptomeninges, and rarely the spinal cord.
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Combined Modality Therapy / methods. Cranial Irradiation / adverse effects. Diagnostic Imaging / methods. Humans. Immunocompetence. Lymphoma, AIDS-Related / therapy. Prognosis. Radiotherapy Planning, Computer-Assisted / methods

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20159361.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 72
  •  go-up   go-down


64. Yotsumoto M, Ichikawa N, Ueno M, Higuchi Y, Asano N, Kobayashi H: CD20-negative CD138-positive leukemic large cell lymphoma with plasmablastic differentiation with an IgH/MYC translocation in an HIV-positive patient. Intern Med; 2009;48(7):559-62
Hazardous Substances Data Bank. GANCICLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antigens, Neoplasm / analysis. Genes, myc. Immunoglobulin Heavy Chains / genetics. Lymphoma, AIDS-Related / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Syndecan-1 / analysis. Translocation, Genetic

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19336959.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Immunoglobulin Heavy Chains; 0 / SDC1 protein, human; 0 / Syndecan-1; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; P9G3CKZ4P5 / Ganciclovir; VAD I protocol
  •  go-up   go-down


65. Northup JK, Gadre SA, Ge Y, Lockhart LH, Velagaleti GV: Do cytogenetic abnormalities precede morphologic abnormalities in a developing malignant condition? Eur J Haematol; 2007 Feb;78(2):152-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Burkitt Lymphoma / genetics. Lymphoma, AIDS-Related / genetics. Lymphoma, Follicular / genetics. Lymphoma, Non-Hodgkin / genetics. Translocation, Genetic
  • [MeSH-minor] Adult. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Chromosomes, Human, Pair 12 / ultrastructure. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 14 / ultrastructure. Chromosomes, Human, Pair 18 / genetics. Chromosomes, Human, Pair 18 / ultrastructure. Chromosomes, Human, Pair 8 / genetics. Chromosomes, Human, Pair 8 / ultrastructure. Chromosomes, Human, X. Clone Cells / pathology. Cyclophosphamide / administration & dosage. Disease Progression. Doxorubicin / administration & dosage. Drug Resistance, Neoplasm. Female. Genes, myc. Humans. Karyotyping. Lymph Nodes / pathology. Male. Mutagenesis, Insertional. Pleural Effusion, Malignant / drug therapy. Pleural Effusion, Malignant / genetics. Pleural Effusion, Malignant / pathology. Prednisone / administration & dosage. Rituximab. Trisomy. Vidarabine / administration & dosage. Vidarabine / analogs & derivatives. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313561.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


66. Armstrong EJ, Bhave P, Wong D, Ursell PC, Kaplan L, Yeghiazarians Y, Ai WZ: Left ventricular rupture due to HIV-associated T-cell lymphoma. Tex Heart Inst J; 2010;37(4):457-60
HIV InSite. treatment guidelines - Cardiac Cardiac Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Left ventricular rupture due to HIV-associated T-cell lymphoma.
  • Patients with lymphoma can develop cardiac involvement that includes malignant pericardial effusions and myocardial infiltration, but extensive myocardial invasion by tumor with resultant rupture has been reported only rarely.
  • We report a case of a patient with human immunodeficiency virus and T-cell lymphoma who presented with signs and symptoms that were suggestive of a non-ST-elevation myocardial infarction.
  • Plans were made for cardiac catheterization, but the patient developed thrombocytopenia after the initiation of heparin and eptifibatide.
  • Cardiac catheterization was deferred, and shortly afterwards he had a witnessed cardiac arrest in the hospital and could not be resuscitated.
  • Autopsy revealed transmural infiltration of the myocardium with lymphoma and resultant rupture of the left ventricular free wall.
  • To our knowledge, this is the 1st reported case of left ventricular free-wall rupture due to transmural infiltration by human-immunodeficiency-virus-associated peripheral T-cell lymphoma.We conclude that noncoronary causes of chest pain, including direct myocardial infiltration, should be considered in immunocompromised patients with lymphoma.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematol Oncol Clin North Am. 2003 Jun;17(3):785-820 [12852656.001]
  • [Cites] N Engl J Med. 2003 Oct 2;349(14):1369-77 [14523146.001]
  • [Cites] Cancer. 1982 Mar 1;49(5):944-51 [7037154.001]
  • [Cites] Eur Heart J. 1987 May;8(5):549-52 [3609049.001]
  • [Cites] Eur J Cardiothorac Surg. 2001 Mar;19(3):365-8 [11251283.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):498-505 [15782345.001]
  • [Cites] Int J Cardiol. 2007 Apr 25;117(2):e84-5 [17331600.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):1008-11 [18464123.001]
  • [Cites] Ann Hematol. 1998 Jul-Aug;77(1-2):75-8 [9760158.001]
  • (PMID = 20844622.001).
  • [ISSN] 1526-6702
  • [Journal-full-title] Texas Heart Institute journal
  • [ISO-abbreviation] Tex Heart Inst J
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA094143
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929872
  • [Keywords] NOTNLM ; Acute coronary syndromes / HIV infections/complications / heart neoplasms/secondary / heart rupture / lymphatic metastasis / lymphoma, AIDS-related / lymphoma, T-cell/pathology / myocardium/pathology / neoplasm invasiveness / pericardium/pathology
  •  go-up   go-down


67. Sharma A, Bajpai J, Raina V, Mohanti BK: HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center. Indian J Cancer; 2010 Jan-Mar;47(1):35-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated non-Hodgkin's lymphoma: experience from a regional cancer center.
  • AIMS: To analyze clinical features and survival in HIV-associated non-Hodgkin lymphoma (NHL) cases registered at Dr BRA Institute Rotary Cancer Hospital of AIIMS, New Delhi.
  • [MeSH-major] HIV Infections / complications. HIV Infections / mortality. Lymphoma, AIDS-Related / mortality. Lymphoma, Non-Hodgkin / mortality. Lymphoma, Non-Hodgkin / virology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols. Antiretroviral Therapy, Highly Active. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult


68. Francischini E, Martins FM, Braz-Silva PH, Magalhães MH, Ortega KL: HIV-associated oral plasmablastic lymphoma and role of adherence to highly active antiretroviral therapy. Int J STD AIDS; 2010 Jan;21(1):68-70
HIV InSite. treatment guidelines - Clinical Implications of Immune Reconstitution in AIDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Anti-Retroviral Agents / therapeutic use. Lymphoma, AIDS-Related / drug therapy. Maxillary Neoplasms / drug therapy. Medication Adherence. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / prevention & control


69. Bishop JA, Westra WH: Plasmablastic lymphoma involving the parotid gland. Head Neck Pathol; 2010 Jun;4(2):148-51
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As an aggressive lymphoma, plasmablastic lymphoma must be considered in the differential diagnosis of a high-grade malignant neoplasm not just in the oral cavity but at non-oral sites including the parotid gland, particularly in an HIV-positive individual.
  • [MeSH-major] HIV Infections / pathology. Lymphoma, AIDS-Related / pathology. Lymphoma, Large-Cell, Immunoblastic / pathology. Parotid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • HIV InSite. treatment guidelines - Palliative Care of Patients with HIV .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1997 Feb 15;89(4):1413-20 [9028965.001]
  • [Cites] Ann Diagn Pathol. 2006 Feb;10(1):8-12 [16414538.001]
  • [Cites] Lancet Infect Dis. 2008 Apr;8(4):261-7 [18353267.001]
  • [Cites] Orbit. 2009;28(6):425-9 [19929677.001]
  • [Cites] Oral Dis. 2009 Jan;15(1):38-45 [18939960.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):138-44 [18647219.001]
  • [Cites] Blood. 2009 Feb 5;113(6):1213-24 [18955561.001]
  • [Cites] Am J Hematol. 2008 Oct;83(10):804-9 [18756521.001]
  • (PMID = 20512642.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Viral; 0 / Membrane Glycoproteins; 0 / RNA-Binding Proteins; 0 / Ribosomal Proteins; 0 / SDC1 protein, human; 0 / Syndecan-1; 135844-68-7 / RPL22 protein, human; EC 3.2.2.5 / Antigens, CD38; EC 3.2.2.5 / CD38 protein, human
  • [Other-IDs] NLM/ PMC2878619
  •  go-up   go-down


70. Bottler T, Kuttenberger J, Hardt N, Oehen HP, Baltensperger M: Non-HIV-associated Kaposi's sarcoma of the tongue. Case report and review of the literature. Int J Oral Maxillofac Surg; 2007 Dec;36(12):1218-20
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma is a frequently seen AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • Genetic Alliance. consumer health - HIV.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614259.001).
  • [ISSN] 0901-5027
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 20
  •  go-up   go-down


71. Feller L, Masipa J, Wood N, Raubenheimer E, Lemmer J: The prognostic significance of facial lymphoedema in HIV-seropositive subjects with Kaposi sarcoma. AIDS Res Ther; 2008;5:2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Kaposi Sarcoma (KS) is a multifocal angioproliferative neoplasm characterized by inflammation, oedema, neoangiogenesis and spindle cell proliferation.
  • RESULTS AND CONCLUSION: Oedema of the face, legs and hands is a prominent feature of HIV-KS and is probably caused by lymphoedema related to the HIV-KS lesions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2000 Jan;142(1):153-6 [10651713.001]
  • [Cites] J Clin Oncol. 1997 Sep;15(9):3085-92 [9294471.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):124-7 [12077591.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2003 Dec;96(6):701-10 [14676761.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] J Surg Oncol. 2004 Sep 1;87(3):146-51 [15334644.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5224-8 [16051964.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Nov;100(5):571-8 [16243242.001]
  • [Cites] Int J Dermatol. 2006 May;45(5):623-6 [16700808.001]
  • [Cites] J Cutan Pathol. 2006 Jul;33(7):474-81 [16872469.001]
  • [Cites] BMC Clin Pathol. 2006;6:7 [17074096.001]
  • [Cites] SADJ. 2006 Aug;61(7):314-7 [17133793.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Oct;104(4):521-9 [17142074.001]
  • [Cites] Lancet Oncol. 2007 Feb;8(2):167-76 [17267331.001]
  • [Cites] J Int Acad Periodontol. 2007 Oct;9(4):129-36 [17987883.001]
  • [Cites] AJR Am J Roentgenol. 1990 Aug;155(2):311-5 [2115258.001]
  • [Cites] West J Med. 1990 Jul;153(1):17-23 [2389573.001]
  • [Cites] J Clin Oncol. 1989 Sep;7(9):1201-7 [2671281.001]
  • [Cites] J Vasc Surg. 1995 Aug;22(2):178-81 [7637119.001]
  • [Cites] Dermatology. 1995;190(4):324-6 [7655117.001]
  • [Cites] Br J Dermatol. 2000 Mar;142(3):501-5 [10735958.001]
  • (PMID = 18226270.001).
  • [ISSN] 1742-6405
  • [Journal-full-title] AIDS research and therapy
  • [ISO-abbreviation] AIDS Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2275292
  •  go-up   go-down


72. Sathekge M, Maes A, Kgomo M, Pottel H, Stolz A, Van De Wiele C: FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging. Q J Nucl Med Mol Imaging; 2010 Dec;54(6):698-703
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG uptake in lymph-nodes of HIV+ and tuberculosis patients: implications for cancer staging.
  • AIM: The incidence of non-AIDS-related cancers (NADCs) in the AIDS-population has surpassed that of the general population.
  • In addition, 30 consecutively referred, previously untreated, HIV and TB negative cancer patients were included.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasms / metabolism. Neoplasms / pathology. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS in Women.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21150859.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


73. Lavolé A, Epaud C, Rosencher L, Gounant V, Wislez M, Cadranel J: [Lung cancer in HIV-positive patients]. Rev Pneumol Clin; 2007 Jun;63(3):167-75
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lung cancer in HIV-positive patients].
  • [Transliterated title] Le cancer broncho-pulmonaire chez les patients séropositifs pour le virus de l'immunodéficience humaine.
  • Since 1996, AIDS-related mortality has declined considerably with the introduction of tritherapy (HAART).
  • This decline in mortality has been associated with an increase in the proportion of deaths caused by cancers unrelated to AIDS, particularly lung cancer.
  • The risk of developing lung cancer is higher in the HIV-seropositive population than in the aged-matched general population, undoubtedly because of the high rate of smoking, particularly among drug abusers, but also because of other reasons which remain to be determined.
  • Mean age at the discovery of lung cancer in HIV+ patients is 45 years, and most are symptomatic.
  • Prospective clinical studies are needed to define a better management strategy for lung cancer in HIV-positive patients.
  • [MeSH-minor] Adenocarcinoma / complications. Age Factors. Antineoplastic Agents / therapeutic use. Antiretroviral Therapy, Highly Active. Humans. Neoplasm Staging. Pneumonectomy. Prognosis. Risk Factors

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675940.001).
  • [ISSN] 0761-8417
  • [Journal-full-title] Revue de pneumologie clinique
  • [ISO-abbreviation] Rev Pneumol Clin
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 66
  •  go-up   go-down


74. Pires I, Silva F, Queiroga FL, Rodrigues P, Henriques R, Pinto CA, Lopes C: Epithelioid hemangiosarcomas of the bovine urinary bladder: a histologic, immunohistochemical, and ultrastructural examination of four tumors. J Vet Diagn Invest; 2010 Jan;22(1):116-9
MedlinePlus Health Information. consumer health - Bladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histologically, each neoplasm was composed of short strands, cords, or nests of epithelioid, round, or slightly spindle-shaped endothelial cells that formed small vascular structures.
  • Neoplastic cells were immunohistochemically positive for factor VIII-related antigen and vimentin, and were negative for cytokeratin and desmin.
  • The present report widens the spectrum of mesenchymal tumors of the bovine urinary bladder and aids in the characterization of these vascular neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093698.001).
  • [ISSN] 1040-6387
  • [Journal-full-title] Journal of veterinary diagnostic investigation : official publication of the American Association of Veterinary Laboratory Diagnosticians, Inc
  • [ISO-abbreviation] J. Vet. Diagn. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Fracasso PM, Blum KA, Ma MK, Tan BR, Wright LP, Goodner SA, Fears CL, Hou W, Arquette MA, Picus J, Denes A, Mortimer JE, Ratner L, Ivy SP, McLeod HL: Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar. Br J Cancer; 2005 Jul 11;93(1):46-53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] AIDS-Related Opportunistic Infections / drug therapy. Antibiotics, Antineoplastic / therapeutic use. Cyclosporins / therapeutic use. Doxorubicin / therapeutic use. Sarcoma, Kaposi / drug therapy
  • [MeSH-minor] Drug Resistance, Multiple. Drug Resistance, Neoplasm. Humans. Liposomes

  • MedlinePlus Health Information. consumer health - HIV/AIDS and Infections.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 Feb 15;52(4):891-6 [1737351.001]
  • [Cites] Eur J Cancer. 1991;27(12):1639-42 [1816768.001]
  • [Cites] Cancer Res. 1994 Feb 15;54(4):987-92 [8313389.001]
  • [Cites] Cancer Res. 1994 Apr 15;54(8):2186-91 [8174126.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):610-8 [8636778.001]
  • [Cites] Cancer Treat Res. 1996;87:3-38 [8886447.001]
  • [Cites] Clin Pharmacol Ther. 1997 Mar;61(3):301-11 [9084455.001]
  • [Cites] J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47 [9262252.001]
  • [Cites] Cancer Res. 1997 Dec 1;57(23):5246-53 [9393743.001]
  • [Cites] J Clin Oncol. 1998 Jul;16(7):2445-51 [9667262.001]
  • [Cites] Clin Cancer Res. 1997 Nov;3(11):2005-15 [9815591.001]
  • [Cites] Oncology (Williston Park). 1999 May;13(5A):183-7 [10370927.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2939-47 [10537363.001]
  • [Cites] Int J Cancer. 2000 Jan 1;85(1):131-41 [10585596.001]
  • [Cites] Anticancer Res. 1999 Jul-Aug;19(4B):2885-91 [10652569.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):1124-34 [10694566.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3093-100 [10963637.001]
  • [Cites] J Clin Oncol. 2001 Feb 1;19(3):832-42 [11157037.001]
  • [Cites] Jpn J Cancer Res. 2001 Feb;92(2):220-30 [11223552.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):206-12 [11330951.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):32-40 [11552228.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1577-90 [11745237.001]
  • [Cites] Clin Cancer Res. 2002 Feb;8(2):413-8 [11839657.001]
  • [Cites] Nat Rev Cancer. 2002 Jan;2(1):48-58 [11902585.001]
  • [Cites] Oncologist. 2003;8(5):411-24 [14530494.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4724-33 [15269145.001]
  • [Cites] Comput Programs Biomed. 1979 Mar;9(2):115-34 [761456.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Dec 15;88(24):11460-4 [1763060.001]
  • [Cites] Br J Cancer. 1991 Dec;64(6):1125-32 [1764376.001]
  • [Cites] Pharm Res. 1993 May;10(5):703-8 [8321835.001]
  • (PMID = 15942626.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA091842
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Cyclosporins; 0 / Liposomes; 121584-18-7 / valspodar; 80168379AG / Doxorubicin
  • [Other-IDs] NLM/ PMC2361488
  •  go-up   go-down


76. Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV: Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer; 2010 Mar 16;102(6):1003-9
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
  • BACKGROUND: Doxorubicin and cyclophosphamide (AC) therapy is an effective treatment for early-stage breast cancer.
  • METHODS: Germ line DNA samples from 230 patients with breast cancer on AC therapy were genotyped for the following SNPs: ABCB1 C1236T, G2677T/A and C3435T, SLC22A16 A146G, T312C, T755C and T1226C, CYP2B6*2, *8, *9, *3, *4 and *5, CYP2C9*2 and *3, CYP3A5*3 and CYP2C19*2.
  • CONCLUSION: Variant alleles in the ABCB1, SLC22A16 and CYP2B6 genes are associated with response to AC therapy in the treatment of breast cancer.
  • [MeSH-minor] Aryl Hydrocarbon Hydroxylases / genetics. Biomarkers, Pharmacological / analysis. Biomarkers, Tumor / genetics. Cytochrome P-450 CYP2B6. Drug Resistance, Neoplasm / genetics. Drug-Related Side Effects and Adverse Reactions / genetics. Female. Gene Frequency. Genotype. Humans. Middle Aged. Organic Cation Transport Proteins / genetics. Oxidoreductases, N-Demethylating / genetics. P-Glycoprotein / genetics. P-Glycoproteins. Polymorphism, Single Nucleotide. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827860887 for PMID:20179710 [PharmGKB] .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Pharmacol Ther. 2001 Aug;70(2):189-99 [11503014.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):447-58 [11470997.001]
  • [Cites] Drug Metab Dispos. 2003 Apr;31(4):398-403 [12642465.001]
  • [Cites] Arthritis Rheum. 2004 Jul;50(7):2202-10 [15248218.001]
  • [Cites] Cancer Res. 1987 Oct 1;47(19):5141-8 [2441861.001]
  • [Cites] Biochim Biophys Acta. 1988 Aug 3;948(1):87-128 [2899442.001]
  • [Cites] J Clin Oncol. 1990 Sep;8(9):1483-96 [2202791.001]
  • [Cites] Cancer Res. 1993 Dec 1;53(23):5629-37 [8242617.001]
  • [Cites] J Biol Chem. 1994 Jun 3;269(22):15419-22 [8195181.001]
  • [Cites] Pharmacogenetics. 1997 Jun;7(3):211-21 [9241661.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):389-98 [9516927.001]
  • [Cites] Lancet. 1998 Sep 19;352(9132):930-42 [9752815.001]
  • [Cites] Lancet. 1999 Feb 27;353(9154):717-9 [10073515.001]
  • [Cites] Drug Metab Dispos. 1999 Jun;27(6):655-66 [10348794.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1086-99 [10419902.001]
  • [Cites] Trends Pharmacol Sci. 1999 Aug;20(8):342-9 [10431214.001]
  • [Cites] AIDS. 2004 Dec 3;18(18):2391-400 [15622315.001]
  • [Cites] Drug Metab Dispos. 2005 Feb;33(2):254-7 [15537833.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Aug 5;333(3):754-62 [15963465.001]
  • [Cites] Pharmacogenomics J. 2005;5(6):365-73 [16116487.001]
  • [Cites] Eur J Pharm Sci. 2006 Jan;27(1):54-61 [16183265.001]
  • [Cites] Science. 2007 Jan 26;315(5811):525-8 [17185560.001]
  • [Cites] Pharmacogenet Genomics. 2007 Feb;17(2):127-36 [17301692.001]
  • [Cites] Pharmacogenet Genomics. 2007 Jun;17(6):431-45 [17502835.001]
  • [Cites] Pharmacogenomics. 2007 Jun;8(6):567-75 [17559346.001]
  • [Cites] Lancet. 2008 Jan 5;371(9606):29-40 [18177773.001]
  • [Cites] Pharmacogenet Genomics. 2008 Jun;18(6):515-23 [18496131.001]
  • [Cites] Br J Clin Pharmacol. 2009 Jan;67(1):50-60 [19076156.001]
  • [Cites] J Antimicrob Chemother. 2009 Apr;63(4):841-3 [19218571.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2639-48 [10561337.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Mar16;281(5):1256-60 [11243870.001]
  • [Cites] Pharmacogenetics. 2001 Jul;11(5):399-415 [11470993.001]
  • [Cites] Pharmacogenomics J. 2003;3(1):53-61 [12629583.001]
  • (PMID = 20179710.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / Biomarkers, Pharmacological; 0 / Biomarkers, Tumor; 0 / Organic Cation Transport Proteins; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / SLC22A16 protein, human; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP2B6 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP2B6; EC 1.5.- / Oxidoreductases, N-Demethylating
  • [Other-IDs] NLM/ PMC2844036
  •  go-up   go-down


77. Rinaldi A, Capello D, Scandurra M, Greiner TC, Chan WC, Bhagat G, Rossi D, Morra E, Paulli M, Rambaldi A, Rancoita PM, Inghirami G, Ponzoni M, Moreno SM, Piris MA, Mian M, Chigrinova E, Zucca E, Favera RD, Gaidano G, Kwee I, Bertoni F: Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. Br J Haematol; 2010 May;149(4):569-77
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-minor] Comparative Genomic Hybridization. DNA, Neoplasm / genetics. Gene Expression Profiling / methods. Genetic Predisposition to Disease. Humans. Immunocompromised Host. Loss of Heterozygosity. Lymphoma, AIDS-Related / genetics. Lymphoma, AIDS-Related / immunology. Recurrence

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20230398.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


78. Aulmann S, Schleibaum J, Penzel R, Schirmacher P, Gebauer G, Sinn HP: Gains of chromosome region 3q26 in intraepithelial neoplasia and invasive squamous cell carcinoma of the vulva are frequent and independent of HPV status. J Clin Pathol; 2008 Sep;61(9):1034-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) usual-type (bowenoid) VIN, which is related to high-risk papillomavirus infection, and (2) differentiated (simplex) VIN, which is associated with chronic inflammation.
  • CONCLUSIONS: Immunohistochemical evaluation of p16 and p53 expression aids in the differential diagnosis of squamous cell alterations of the vulva.
  • [MeSH-minor] Aged. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Female. Gene Expression. Gene Expression Regulation, Neoplastic. Genes, p16. Genes, p53. Humans. In Situ Hybridization, Fluorescence. Middle Aged. Neoplasm Invasiveness / genetics. Papillomavirus Infections / complications. Polymerase Chain Reaction. Tumor Suppressor Protein p53 / analysis. Tumor Virus Infections / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18559375.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


79. Pak F, Pyakural P, Kokhaei P, Kaaya E, Pourfathollah AA, Selivanova G, Biberfeld P: HHV-8/KSHV during the development of Kaposi's sarcoma: evaluation by polymerase chain reaction and immunohistochemistry. J Cutan Pathol; 2005 Jan;32(1):21-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The human gamma-herpes virus-8 (HHV-8) was first described in AIDS-related Kaposi's sarcoma (KS) tumour samples.
  • In this study, we report comparative studies on paraffin-embedded biopsies of AIDS-related KS (AKS) and endemic KS (EKS) with regard to HHV-8 content as evaluated using polymerase chain reaction (PCR) and immunohistochemistry.
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Antigens, CD34 / analysis. Antigens, Viral / analysis. Cell Count. DNA, Neoplasm / analysis. Humans. Immunohistochemistry. Nuclear Proteins / analysis. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660651.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Viral; 0 / DNA, Neoplasm; 0 / DNA, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  •  go-up   go-down


80. Grigorian A, Hurford R, Chao Y, Patrick C, Langford TD: Alterations in the Notch4 pathway in cerebral endothelial cells by the HIV aspartyl protease inhibitor, nelfinavir. BMC Neurosci; 2008 Feb 26;9:27
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, PIs, particularly Nelfinavir, were reported to disrupt Notch signaling in the HIV-related endothelial cell neoplasm, Kaposi's sarcoma.

  • Genetic Alliance. consumer health - HIV.
  • Hazardous Substances Data Bank. SAQUINAVIR .
  • Hazardous Substances Data Bank. INDINAVIR SULFATE .
  • Hazardous Substances Data Bank. NELFINAVIR MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2000 Jan;25(1):1-6 [10637601.001]
  • [Cites] J Biol Chem. 2003 Aug 22;278(34):32227-35 [12794074.001]
  • [Cites] Nature. 1993 Apr 8;362(6420):557-60 [8385271.001]
  • [Cites] Stroke. 1993 Dec;24(12):2121-7 [8248999.001]
  • [Cites] Clin Pharmacokinet. 1997 Mar;32(3):194-209 [9084959.001]
  • [Cites] J Neurobiol. 1997 May;32(5):469-80 [9110259.001]
  • [Cites] Drug Resist Updat. 2003 Aug;6(4):173-81 [12962683.001]
  • [Cites] Bioessays. 2004 Mar;26(3):225-34 [14988924.001]
  • [Cites] Mol Cancer Ther. 2004 Apr;3(4):473-9 [15078991.001]
  • [Cites] Genes Cells. 1997 Mar;2(3):213-24 [9189758.001]
  • [Cites] AIDS Treat News. 1997 Aug 15;(No 277):1-4 [11364559.001]
  • [Cites] Virology. 1998 Oct 25;250(2):255-62 [9792836.001]
  • [Cites] J Biol Chem. 2004 Nov 19;279(47):48615-9 [15456788.001]
  • [Cites] J Endocrinol. 2004 Dec;183(3):445-54 [15590971.001]
  • [Cites] Cell Mol Neurobiol. 2005 Feb;25(1):181-99 [15962513.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):425-33 [16053514.001]
  • [Cites] Pharm Res. 2005 Aug;22(8):1259-68 [16078135.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8256-65 [16166302.001]
  • [Cites] Oncogene. 2005 Sep 22;24(42):6333-44 [15940249.001]
  • [Cites] BMC Cell Biol. 2006;7:10 [16507111.001]
  • [Cites] Curr HIV Res. 2006 Jul;4(3):259-66 [16842079.001]
  • [Cites] Microvasc Res. 2006 Jul-Sep;72(1-2):12-9 [16750838.001]
  • [Cites] J Virol. 2006 Oct;80(19):9697-709 [16973574.001]
  • [Cites] Cancer Res. 2006 Sep 15;66(18):9252-9 [16982770.001]
  • [Cites] Biol Chem. 2006 Oct-Nov;387(10-11):1337-46 [17081104.001]
  • [Cites] Neoplasia. 2006 Nov;8(11):889-95 [17132220.001]
  • [Cites] J Pharmacol Exp Ther. 2007 Jan;320(1):291-9 [17038510.001]
  • [Cites] J Acquir Immune Defic Syndr. 2007 Apr 15;44(5):493-9 [17245228.001]
  • [Cites] Biochem Pharmacol. 2007 May 15;73(10):1573-81 [17328866.001]
  • [Cites] J Pharm Pharmacol. 2007 Jul;59(7):947-53 [17637189.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(3):261-9 [15470273.001]
  • [Cites] Am J Pathol. 1999 Dec;155(6):1915-27 [10595922.001]
  • [Cites] J Neurosci. 2000 Mar 1;20(5):1657-65 [10684867.001]
  • [Cites] AIDS. 2000 Apr 14;14(6):743-4 [10807198.001]
  • [Cites] Biochem Biophys Res Commun. 2001 Aug 24;286(3):484-92 [11511084.001]
  • [Cites] Dev Cell. 2001 Dec;1(6):725-6 [11740931.001]
  • [Cites] J Biol Chem. 2001 Dec 21;276(51):47840-3 [11602580.001]
  • [Cites] J Cell Biol. 2002 Jan 7;156(1):149-60 [11781339.001]
  • [Cites] Nat Med. 2002 Mar;8(3):225-32 [11875492.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1095-7 [11884509.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2830-41 [11909975.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7021-6 [12011461.001]
  • [Cites] Curr Biol. 2002 Jun 25;12(12):1006-11 [12123574.001]
  • [Cites] Microvasc Res. 2002 Nov;64(3):372-83 [12453432.001]
  • [Cites] Mol Cell Biol. 2003 Jan;23(1):14-25 [12482957.001]
  • [Cites] Lancet. 2003 Feb 15;361(9357):605-8 [12598159.001]
  • [Cites] Semin Cell Dev Biol. 2003 Apr;14(2):113-9 [12651094.001]
  • [Cites] J Biol Chem. 2003 Aug 15;278(33):31277-85 [12764143.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(3):287-302 [15470276.001]
  • (PMID = 18302767.001).
  • [ISSN] 1471-2202
  • [Journal-full-title] BMC neuroscience
  • [ISO-abbreviation] BMC Neurosci
  • [Language] ENG
  • [Grant] United States / NIMH NIH HHS / MH / K01 MH071206; United States / NINDS NIH HHS / NS / R21 NS055639; United States / NHLBI NIH HHS / HL / T35HL007491-25; United States / NIMH NIH HHS / MH / R24 MH059745; United States / NIA NIH HHS / AG / T35AG026757; United States / NINDS NIH HHS / NS / NS055639; United States / NIMH NIH HHS / MH / R01 MH062962; United States / NIMH NIH HHS / MH / MH071206; United States / NIA NIH HHS / AG / T35 AG026757; United States / NHLBI NIH HHS / HL / T35 HL007491; United States / NIMH NIH HHS / MH / MH59745; United States / NIMH NIH HHS / MH / MH62962
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / C14orf129 protein, human; 0 / HIV Protease Inhibitors; 0 / NOTCH4 protein, human; 0 / Proto-Oncogene Proteins; 0 / Reactive Oxygen Species; 0 / Receptor, Notch1; 0 / Receptors, Notch; 0 / Repressor Proteins; 1406-18-4 / Vitamin E; 5W6YA9PKKH / Indinavir; EC 3.4.23.- / Aspartic Acid Endopeptidases; HO3OGH5D7I / Nelfinavir; L3JE09KZ2F / Saquinavir; O3J8G9O825 / Ritonavir
  • [Other-IDs] NLM/ PMC2268698
  •  go-up   go-down


81. Wang X, Wang X, Liang D, Lan K, Guo W, Ren G: Classic Kaposi's sarcoma in Han Chinese and useful tools for differential diagnosis. Oral Oncol; 2010 Sep;46(9):654-6
MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Kaposi's sarcoma (KS) is a common AIDS-related malignant neoplasm in the head and neck region, especially in the oral cavity, but is rarely described in the HIV-negative and non-immunosuppressed individual.

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20656545.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


82. Ye ZB, Ma T, Li H, Jin XL, Xu HM: Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J Gastroenterol; 2007 Mar 21;13(11):1747-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The expressions of IL-12 and IL-18 from 50 samples of gastric cancer tissue were analyzed by immunohistochemistry, and microvessel density (MVD) was determined with microscopic imaging analysis system.
  • IL-12 was significantly associated with pathologic differentiation, depth of invasion, lymph node metastasis, distant metastasis, and TNM stage, and IL-18 was closely related to distant metastasis.
  • Intratumoral IL-12 and IL-18 expressions were not statistically related to MVD scoring.
  • CONCLUSION: The positive expressions of IL-12 and IL-18 can play an important role in progression and metastasis of gastric cancer, and IL-12 might be an independent factor of poor prognosis in gastric carcinoma.
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Metastasis. Neoplasm Staging. Prognosis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 1999 Dec;13(15):2195-202 [10593867.001]
  • [Cites] Int J Urol. 2004 Aug;11(8):647-52 [15285756.001]
  • [Cites] Int J Biol Markers. 2001 Apr-Jun;16(2):126-9 [11471895.001]
  • [Cites] Clin Otolaryngol Allied Sci. 2001 Aug;26(4):302-6 [11559342.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2050-5 [11596019.001]
  • [Cites] Auris Nasus Larynx. 2004 Sep;31(3):239-45 [15364358.001]
  • [Cites] In Vivo. 1993 May-Jun;7(3):265-9 [8357968.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):38-43 [8847724.001]
  • [Cites] J Exp Med. 1997 Mar 3;185(5):817-24 [9120387.001]
  • [Cites] J Clin Invest. 1998 Mar 15;101(6):1441-52 [9502787.001]
  • [Cites] J Immunol. 1999 May 1;162(9):5070-7 [10227975.001]
  • [Cites] AIDS Res Hum Retroviruses. 2005 Jul;21(7):629-43 [16060834.001]
  • [Cites] Cytokine. 2002 Aug 7;19(3):126-37 [12242079.001]
  • [Cites] FASEB J. 2003 Apr;17(6):728-30 [12594171.001]
  • [Cites] Leuk Res. 2004 Jan;28(1):91-5 [14630085.001]
  • [Cites] Curr Opin Immunol. 2004 Apr;16(2):157-62 [15023407.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Jan 18;97(2):734-9 [10639148.001]
  • (PMID = 17461482.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-18; 187348-17-0 / Interleukin-12
  • [Other-IDs] NLM/ PMC4146958
  •  go-up   go-down


83. Fill S, Taran A, Schulz HU, Kahl S, Kalinski T, Smith B, Costa SD: Sister Mary Joseph's nodule as the first sign of pregnancy-associated gastric cancer: a case report. World J Gastroenterol; 2008 Feb 14;14(6):951-3
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sister Mary Joseph's nodule as the first sign of pregnancy-associated gastric cancer: a case report.
  • Sister Mary Joseph's nodule is an inconspicuous and uncommon clinical sign of advanced malignant disease, especially gastric cancer.
  • Pregnancy-associated gastric cancer is an extremely rare condition and can be difficult to diagnose, due to the absence or misinterpretation of symptoms as pregnancy-related.
  • Diagnostic aids, such as a basic chemistry panel and imaging techniques, may not show any abnormalities.
  • We present a case of a 37-year-old pregnant patient whose umbilical nodule was the first presenting physical sign of gastric cancer, which had metastasized throughout the abdominal and pelvic regions.
  • [MeSH-minor] Adult. Female. Humans. Neoplasm Staging. Pregnancy

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cancer Res Clin Oncol. 2000 Apr;126(4):233-7 [10782897.001]
  • [Cites] Arch Gynecol Obstet. 2006 Apr;274(1):47-9 [16283407.001]
  • [Cites] Scand J Gastroenterol. 2003 Dec;38(12):1249-55 [14750645.001]
  • [Cites] Hautarzt. 2004 Feb;55(2):186-9 [14968331.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 18;96(4):261-8 [14970275.001]
  • [Cites] J Chronic Dis. 1966 Oct;19(10):1113-7 [5966767.001]
  • [Cites] World J Surg. 1991 Mar-Apr;15(2):293-7, discussion 298 [2031366.001]
  • [Cites] Arch Dermatol. 1992 Apr;128(4):548-9, 551-2 [1580666.001]
  • [Cites] J Surg Oncol. 1994 Jan;55(1):3-6 [8289449.001]
  • [Cites] J Surg Oncol. 1995 Mar;58(3):191-5 [7898116.001]
  • [Cites] Arch Gynecol Obstet. 1996;258(3):151-4 [8781704.001]
  • [Cites] Hepatogastroenterology. 1996 Sep-Oct;43(11):1273-80 [8908562.001]
  • [Cites] Cutis. 1997 Dec;60(6):297-8 [9426970.001]
  • [Cites] Hepatogastroenterology. 1997 Nov-Dec;44(18):1641-5 [9427036.001]
  • [Cites] Cancer. 1998 Jul 1;83(1):25-33 [9655289.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] N Engl J Med. 2005 May 5;352(18):1913 [15872206.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2003 Apr 25;107(2):208-9 [12648871.001]
  • (PMID = 18240358.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2687068
  •  go-up   go-down


84. Bruce AG, Bakke AM, Bielefeldt-Ohmann H, Ryan JT, Thouless ME, Tsai CC, Rose TM: High levels of retroperitoneal fibromatosis (RF)-associated herpesvirus in RF lesions in macaques are associated with ORF73 LANA expression in spindleoid tumour cells. J Gen Virol; 2006 Dec;87(Pt 12):3529-38
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Two distinct lineages of rhadinoviruses related to Kaposi's sarcoma (KS)-associated herpesvirus (KSHV; Human herpesvirus 8), the causative agent of KS, have been identified.
  • In macaques, the RV1 lineage is represented by retroperitoneal fibromatosis (RF) herpesvirus (RFHV), the homologue of KSHV, whilst the RV2 lineage is represented by rhesus rhadinovirus (RRV), a more distantly related virus.
  • Real-time quantitative PCR was used to estimate the loads of RV1 and RV2 rhadinoviruses in simian acquired immunodeficiency syndrome-associated RF (SAIDS-RF), a neoplasm of macaques with similarities to AIDS-associated KS.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17098967.001).
  • [ISSN] 0022-1317
  • [Journal-full-title] The Journal of general virology
  • [ISO-abbreviation] J. Gen. Virol.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / K02 AI49275; United States / NCRR NIH HHS / RR / RR00166; United States / NCRR NIH HHS / RR / RR13154
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / DNA, Viral; 0 / Nuclear Proteins; 0 / latency-associated nuclear antigen
  •  go-up   go-down


85. Gross O, Gewies A, Finger K, Schäfer M, Sparwasser T, Peschel C, Förster I, Ruland J: Card9 controls a non-TLR signalling pathway for innate anti-fungal immunity. Nature; 2006 Aug 10;442(7103):651-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fungal infections are increasing worldwide due to the marked rise in immunodeficiencies including AIDS; however, immune responses to fungi are poorly understood.
  • Dectin-1 represents the prototype of innate non-Toll-like receptors (TLRs) containing immunoreceptor tyrosine-based activation motifs (ITAMs) related to those of adaptive antigen receptors.
  • [MeSH-minor] Animals. Antigens, Fungal / immunology. CARD Signaling Adaptor Proteins. Candida albicans / immunology. Caspases / metabolism. Cytokines / biosynthesis. Cytokines / immunology. Intracellular Signaling Peptides and Proteins / metabolism. Lectins, C-Type. Lymphocyte Activation / immunology. Membrane Proteins / metabolism. Mice. NF-kappa B / metabolism. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Protein-Tyrosine Kinases / metabolism. Toll-Like Receptors. Zymosan / immunology


86. Partridge AH, Archer L, Kornblith AB, Gralow J, Grenier D, Perez E, Wolff AC, Wang X, Kastrissios H, Berry D, Hudis C, Winer E, Muss H: Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104. J Clin Oncol; 2010 May 10;28(14):2418-22
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: adherence companion study 60104.
  • PATIENTS AND METHODS: Cancer and Leukemia Group B study CALGB 49907 was a randomly assigned trial comparing standard chemotherapy versus oral chemotherapy with capecitabine in patients age 65 years or older with early-stage breast cancer.
  • Adherence was calculated as the number of doses taken divided by doses expected, taking into account toxicity-related dosing changes.
  • Adherence was not related to age, tumor stage, or hormone receptor status.
  • CONCLUSION: Most older women with early-stage breast cancer were adherent to short-term oral chemotherapy in a randomized clinical trial.

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mastectomy.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):322-8 [11208822.001]
  • [Cites] J Clin Oncol. 2010 May 10;28(14):2423-9 [20385997.001]
  • [Cites] J Natl Cancer Inst. 2002 May 1;94(9):652-61 [11983753.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2680-8 [12039930.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):602-6 [12586795.001]
  • [Cites] JAMA. 1989 Jun 9;261(22):3273-7 [2716163.001]
  • [Cites] Prev Med. 1991 Jan;20(1):132-46 [2008422.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1189-97 [8501505.001]
  • [Cites] AIDS. 1998 Dec 3;12(17):2295-303 [9863872.001]
  • [Cites] Oncology. 2006;71(1-2):1-9 [17344666.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):549-55 [18071188.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):556-62 [18180462.001]
  • [Cites] Value Health. 2008 Jan-Feb;11(1):44-7 [18237359.001]
  • [Cites] Clin Nurs Res. 2008 May;17(2):89-97 [18387881.001]
  • [Cites] Br J Cancer. 2008 Dec 2;99(11):1763-8 [18985046.001]
  • [Cites] CA Cancer J Clin. 2009 Jan-Feb;59(1):56-66 [19147869.001]
  • [Cites] N Engl J Med. 2009 May 14;360(20):2055-65 [19439741.001]
  • [Cites] Breast Cancer Res Treat. 2009 Oct;117(3):615-23 [19294501.001]
  • [Cites] Clin Ther. 2001 Aug;23(8):1296-310 [11558866.001]
  • (PMID = 20368559.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA032291; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA77406; United States / NCI NIH HHS / CA / CA32291; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA077202; United States / NCI NIH HHS / CA / U10 CA021115; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / CA77651; United States / NCI NIH HHS / CA / U10 CA033601; United States / NCI NIH HHS / CA / U10 CA105409; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA077651; United States / NCI NIH HHS / CA / CA105409; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA77202; United States / NCI NIH HHS / CA / CA25224; United States / NCI NIH HHS / CA / .CA31946; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / U10 CA025224
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2881723
  •  go-up   go-down


87. Lambert M, Gannagé M, Karras A, Abel M, Legendre C, Kerob D, Agbalika F, Girard PM, Lebbe C, Caillat-Zucman S: Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood; 2006 Dec 1;108(12):3871-80
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We compared CD8 T-cell responses to HHV8 latent (K12) and lytic (glycoprotein B, ORF6, ORF61, and ORF65) antigens in patients who spontaneously controlled the infection and in patients with posttransplantation, AIDS-related, or classical KS.
  • [MeSH-minor] Aged. Cancer Vaccines / immunology. Cancer Vaccines / therapeutic use. Female. Herpesvirus Vaccines / immunology. Herpesvirus Vaccines / therapeutic use. Humans. Immunotherapy, Adoptive / methods. Male. Middle Aged. Neoplasm Regression, Spontaneous / immunology. Neoplasm Regression, Spontaneous / pathology. Transplants / adverse effects

  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16926293.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / Cancer Vaccines; 0 / Herpesvirus Vaccines
  •  go-up   go-down


88. Bekar A, Bilgin H, Korfali G, Korfali E, Kocaeli H, Taskapiğlu O: Minimally invasive awake craniotomy using Steiner-Lindquist stereotactic laser guidance. Minim Invasive Neurosurg; 2009 Aug;52(4):176-9
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, stereotactic laser guidance aids in performing minimally invasive procedures related to the radical resection of lesions located in eloquent and non-eloquent brain regions.
  • [MeSH-minor] Adult. Aged. Female. Glioblastoma / pathology. Glioblastoma / surgery. Humans. Lasers. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis / therapy. Postoperative Care. Postoperative Complications / prevention & control. Preoperative Care. Retrospective Studies. Treatment Outcome. Wakefulness / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 19838971.001).
  • [ISSN] 1439-2291
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


89. Martinez V, Caumes E, Gambotti L, Ittah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N: Remission from Kaposi's sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. Br J Cancer; 2006 Apr 10;94(7):1000-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epidemiologic and HIV-related clinical and biological parameters were recorded at KS diagnosis (baseline) and every 6 months thereafter.
  • Fourteen deaths occurred after a median follow-up of 37.5 months, eight of which were KS related.
  • [MeSH-minor] Adult. Aged. CD4 Lymphocyte Count. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome. Viral Load


90. Célestin Schartz NE, Chevret S, Paz C, Kerob D, Verola O, Morel P, Lebbé C: Imiquimod 5% cream for treatment of HIV-negative Kaposi's sarcoma skin lesions: A phase I to II, open-label trial in 17 patients. J Am Acad Dermatol; 2008 Apr;58(4):585-91
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Kaposi's sarcoma (KS), a virus-associated neoplasm, can be treated locally or systemically with interferon alfa.
  • The main efficacy end points were the safety of topical imiquimod and the overall clinical response in patients evaluated on the basis of modified AIDS Clinical Trials Group criteria at 36 weeks.
  • [MeSH-minor] Administration, Topical. Aged. Drug-Related Side Effects and Adverse Reactions. Female. Humans. Male. Middle Aged. Patient Compliance. Prospective Studies

  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - Kaposi's Sarcoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068265.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 99011-02-6 / imiquimod
  •  go-up   go-down


91. Olivero OA, Vazquez IL, Cooch CC, Ming J, Keller E, Yu M, Borojerdi JP, Braun HM, McKee E, Poirier MC: Long-term AZT exposure alters the metabolic capacity of cultured human lymphoblastoid cells. Toxicol Sci; 2010 May;115(1):109-17
Hazardous Substances Data Bank. ZIDOVUDINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An exposure-related increase in the frequency of micronuclei (MN) was observed in cells exposed to either 10 or 800 microM AZT during P(1)-P(14).

  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pharmazie. 2001 Jun;56(6):492-500 [11446172.001]
  • [Cites] Environ Mol Mutagen. 2009 Oct;50(8):718-24 [19562754.001]
  • [Cites] Biochem Pharmacol. 2002 Jul 15;64(2):239-46 [12123744.001]
  • [Cites] Cell Mol Life Sci. 2002 Aug;59(8):1327-46 [12363036.001]
  • [Cites] Int J Mol Med. 2003 Jun;11(6):743-7 [12736716.001]
  • [Cites] Life Sci. 2004 Jan 2;74(7):835-42 [14659972.001]
  • [Cites] Environ Mol Mutagen. 2004;43(1):3-9 [14743340.001]
  • [Cites] Mutat Res. 2004 Mar 22;547(1-2):63-9 [15013700.001]
  • [Cites] Mutagenesis. 2004 Jul;19(4):307-11 [15215330.001]
  • [Cites] Cardiovasc Toxicol. 2004;4(2):155-67 [15371631.001]
  • [Cites] Environ Mol Mutagen. 2004;44(4):321-8 [15476197.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Oct;82(20):7096-100 [2413459.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7 [2430286.001]
  • [Cites] N Engl J Med. 1987 Jul 23;317(4):192-7 [3299090.001]
  • [Cites] J Biol Chem. 1988 Jan 5;263(1):375-82 [3335503.001]
  • [Cites] N Engl J Med. 1989 Sep 14;321(11):726-38 [2671731.001]
  • [Cites] Clin Lab Haematol. 1990;12(2):177-84 [2208948.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Oct 30;188(2):712-8 [1359886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2960-4 [8464912.001]
  • [Cites] J Acquir Immune Defic Syndr. 1993 Dec;6(12):1287-96 [8254464.001]
  • [Cites] Toxicol Lett. 1994 Feb 1;70(2):235-42 [7905210.001]
  • [Cites] Mutat Res. 1994 Apr;321(1-2):113-8 [7510839.001]
  • [Cites] AIDS Res Hum Retroviruses. 1995 Jul;11(7):805-11 [7546907.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jan 1;8(1):1-9 [8548339.001]
  • [Cites] Mutat Res. 1996 Jul 5;368(3-4):301-7 [8692236.001]
  • [Cites] AIDS Res Hum Retroviruses. 1996 Feb 10;12(3):223-8 [8835200.001]
  • [Cites] Mutat Res. 1997 May 23;390(3):223-31 [9186571.001]
  • [Cites] Biochem Pharmacol. 1998 Aug 1;56(3):389-95 [9744577.001]
  • [Cites] Nucleosides Nucleotides Nucleic Acids. 2004;23(11):1797-811 [15598079.001]
  • [Cites] New Microbiol. 2004 Apr;27(2 Suppl 1):63-9 [15646066.001]
  • [Cites] Mutat Res. 2005 Mar 1;570(2):227-35 [15708581.001]
  • [Cites] Mutagenesis. 2005 Mar;20(2):139-46 [15784690.001]
  • [Cites] Environ Mol Mutagen. 2007 Apr-May;48(3-4):215-23 [16395695.001]
  • [Cites] Toxicol Appl Pharmacol. 2008 Apr 15;228(2):158-64 [18206198.001]
  • [Cites] Cardiovasc Toxicol. 2008 Summer;8(2):57-69 [18446447.001]
  • [Cites] Med Res Rev. 2008 Sep;28(5):797-820 [18459168.001]
  • [Cites] FEBS J. 2009 Jan;276(2):571-80 [19087190.001]
  • [Cites] Environ Mol Mutagen. 2002;39(4):282-95 [12112380.001]
  • (PMID = 20106944.001).
  • [ISSN] 1096-0929
  • [Journal-full-title] Toxicological sciences : an official journal of the Society of Toxicology
  • [ISO-abbreviation] Toxicol. Sci.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / DNA Adducts; 4B9XT59T7S / Zidovudine; 9007-49-2 / DNA; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1; VC2W18DGKR / Thymidine
  • [Other-IDs] NLM/ PMC2855349
  •  go-up   go-down


92. Koelle DM, Gonzalez JC, Johnson AS: Homing in on the cellular immune response to HSV-2 in humans. Am J Reprod Immunol; 2005 Apr;53(4):172-81
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Molecules related to lymphocyte rolling adhesion were studied by flow cytometry and cell binding.

  • MedlinePlus Health Information. consumer health - Genital Herpes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 Blackwell Munksgaard.
  • [Cites] J Immunol. 2000 Apr 1;164(7):3465-70 [10725697.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):4244-9 [10754321.001]
  • [Cites] J Exp Med. 2000 May 1;191(9):1459-66 [10790421.001]
  • [Cites] Invest Ophthalmol Vis Sci. 2000 Aug;41(9):2607-12 [10937573.001]
  • [Cites] J Immunol Methods. 2000 Oct 20;244(1-2):81-9 [11033021.001]
  • [Cites] J Virol. 2000 Dec;74(23):10930-8 [11069987.001]
  • [Cites] J Virol. 2000 Dec;74(23):11422-5 [11070045.001]
  • [Cites] J Immunol. 2000 Dec 15;165(12):6677-81 [11120783.001]
  • [Cites] J Immunol. 2001 Mar 15;166(6):4049-58 [11238653.001]
  • [Cites] J Virol. 2001 Apr;75(7):3077-88 [11238834.001]
  • [Cites] J Virol. 2001 Nov;75(22):11178-84 [11602757.001]
  • [Cites] J Virol. 2002 Jan;76(1):9-18 [11739667.001]
  • [Cites] Eur J Immunol. 2003 Apr;33(4):1052-62 [12672071.001]
  • [Cites] J Immunol. 2003 Apr 15;170(8):4380-8 [12682275.001]
  • [Cites] Methods. 2003 Mar;29(3):213-26 [12725787.001]
  • [Cites] Immunity. 2003 May;18(5):593-603 [12753737.001]
  • [Cites] AIDS. 2003 May 23;17(8):1139-44 [12819514.001]
  • [Cites] J Exp Med. 2003 Aug 4;198(3):513-20 [12900525.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1771-8 [12738675.001]
  • [Cites] Immunol Rev. 2003 Oct;195:58-71 [12969310.001]
  • [Cites] Science. 2003 Sep 26;301(5641):1925-8 [14512632.001]
  • [Cites] Ernst Schering Res Found Workshop. 2004;(44):95-107 [14579776.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12899-904 [14566059.001]
  • [Cites] Am J Pathol. 2003 Dec;163(6):2179-84 [14633592.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5769-77 [14634085.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1575-81 [14734737.001]
  • [Cites] Trends Immunol. 2004 May;25(5):230-4 [15099562.001]
  • [Cites] J Exp Med. 2004 May 3;199(9):1265-75 [15123746.001]
  • [Cites] Immunity. 2004 Oct;21(4):527-38 [15485630.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):226-33 [3880773.001]
  • [Cites] J Exp Med. 1986 Aug 1;164(2):661-6 [3723080.001]
  • [Cites] N Engl J Med. 2000 Mar 23;342(12):844-50 [10727588.001]
  • [Cites] J Exp Med. 2002 Jan 7;195(1):135-41 [11781372.001]
  • [Cites] J Invest Dermatol. 2001 Dec;117(6):1464-70 [11886510.001]
  • [Cites] Blood. 2002 Jun 1;99(11):4063-9 [12010808.001]
  • [Cites] Br J Haematol. 2002 Aug;118(2):654-62 [12139761.001]
  • [Cites] J Clin Invest. 2002 Aug;110(4):537-48 [12189248.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1652-61 [12444179.001]
  • [Cites] J Virol. 2003 Feb;77(3):2081-92 [12525643.001]
  • [Cites] J Exp Med. 2003 Jan 20;197(2):153-62 [12538655.001]
  • [Cites] Am J Pathol. 1990 May;136(5):1053-68 [1693467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Aug 1;88(15):6523-7 [1713680.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1461-6 [1720810.001]
  • [Cites] J Virol. 1994 May;68(5):2803-10 [7512152.001]
  • [Cites] J Infect Dis. 1994 May;169(5):956-61 [8169426.001]
  • [Cites] Eye (Lond). 1995;9 ( Pt 3):261-7 [7556729.001]
  • [Cites] J Immunol. 1997 Jan 15;158(2):574-9 [8992970.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10289-94 [9294203.001]
  • [Cites] J Clin Invest. 1998 Apr 1;101(7):1500-8 [9525993.001]
  • [Cites] J Virol. 1998 Sep;72(9):7476-83 [9696844.001]
  • [Cites] Immunology. 1999 Feb;96(2):272-7 [10233705.001]
  • [Cites] J Invest Dermatol. 1999 May;112(5):716-22 [10233762.001]
  • [Cites] Int Arch Allergy Immunol. 1999 Jul;119(3):212-22 [10436393.001]
  • [Cites] Nature. 1999 Aug 19;400(6746):776-80 [10466728.001]
  • [Cites] J Invest Dermatol. 1999 Oct;113(4):574-8 [10504443.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):243-54 [15609235.001]
  • [Cites] J Virol. 2003 Feb;77(4):2400-9 [12551977.001]
  • [Cites] J Virol. 2003 Apr;77(7):4127-38 [12634371.001]
  • (PMID = 15760378.001).
  • [ISSN] 1046-7408
  • [Journal-full-title] American journal of reproductive immunology (New York, N.Y. : 1989)
  • [ISO-abbreviation] Am. J. Reprod. Immunol.
  • [Language] ENG
  • [Grant] United States / NIAID NIH HHS / AI / P01 AI030731; United States / NIAID NIH HHS / AI / R01 AI050132; United States / NIAID NIH HHS / AI / AI30731; United States / NIAID NIH HHS / AI / AI50132
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CTAGE1 protein, human; 0 / E-Selectin; 0 / Epitopes; 0 / Membrane Glycoproteins; 0 / Receptors, Antigen, T-Cell, alpha-beta
  • [Other-IDs] NLM/ NIHMS3287; NLM/ PMC1255910
  •  go-up   go-down


93. Wlodarski MW, Nearman Z, Jankowska A, Babel N, Powers J, Leahy P, Volk HD, Maciejewski JP: Phenotypic differences between healthy effector CTL and leukemic LGL cells support the notion of antigen-triggered clonal transformation in T-LGL leukemia. J Leukoc Biol; 2008 Mar;83(3):589-601
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite a strikingly similar gene expression profile between T-LGL clones and their healthy counterparts, important phenotypic differences were identified, including up-modulation of TNFRS9, myeloid cell leukemia sequence 1, IFN-gamma, and IFN-gamma-related genes, and several integrins/adhesion molecules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Neurosci. 2002 Jun;25(6):313-9 [12086750.001]
  • [Cites] J Clin Invest. 2002 Jul;110(2):185-92 [12122110.001]
  • [Cites] Blood. 2002 Aug 15;100(4):1449-53 [12149230.001]
  • [Cites] Int J Oncol. 2003 Jan;22(1):33-9 [12469182.001]
  • [Cites] Blood. 2003 Apr 15;101(8):3198-204 [12480700.001]
  • [Cites] Hematol J. 2003;4(1):18-25 [12692516.001]
  • [Cites] Nat Immunol. 2003 May;4(5):410-5 [12719730.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):185-95 [12876667.001]
  • [Cites] Semin Hematol. 2003 Jul;40(3):213-20 [12876670.001]
  • [Cites] J Exp Med. 1997 Nov 3;186(9):1407-18 [9348298.001]
  • [Cites] J Exp Med. 1998 Mar 2;187(5):763-74 [9480986.001]
  • [Cites] Br J Haematol. 1998 May;101(2):318-24 [9609528.001]
  • [Cites] J Exp Med. 1998 Jun 1;187(11):1849-62 [9607925.001]
  • [Cites] Blood. 1998 Dec 15;92(12):4771-7 [9845544.001]
  • [Cites] N Engl J Med. 1999 Jan 28;340(4):278-84 [9920952.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • [Cites] J Cell Biol. 2000 Mar 20;148(6):1151-8 [10725328.001]
  • [Cites] Blood Rev. 1999 Dec;13(4):230-40 [10741898.001]
  • [Cites] Arthritis Rheum. 2000 Apr;43(4):834-43 [10765928.001]
  • [Cites] Blood. 2000 Aug 1;96(3):1021-9 [10910918.001]
  • [Cites] Eur J Immunol. 2000 Jul;30(7):1797-806 [10940868.001]
  • [Cites] J Immunol. 2000 Oct 1;165(7):4127-32 [11034425.001]
  • [Cites] J Immunol. 2000 Nov 15;165(10):5729-37 [11067931.001]
  • [Cites] Immunology. 2001 Jan;102(1):44-52 [11168636.001]
  • [Cites] J Clin Invest. 2001 Feb;107(3):351-62 [11160159.001]
  • [Cites] J Immunol. 2001 Feb 15;166(4):2364-71 [11160294.001]
  • [Cites] Annu Rev Immunol. 2001;19:65-91 [11244031.001]
  • [Cites] Leuk Res. 2001 Aug;25(8):699-708 [11397476.001]
  • [Cites] Blood. 2001 Jul 1;98(1):165-73 [11418476.001]
  • [Cites] Blood. 2001 Nov 1;98(9):2817-27 [11675356.001]
  • [Cites] Am J Pathol. 2001 Nov;159(5):1861-8 [11696446.001]
  • [Cites] Exp Hematol. 2001 Nov;29(11):1270-7 [11698122.001]
  • [Cites] Curr Dir Autoimmun. 2002;5:1-29 [11826753.001]
  • [Cites] Eur J Immunol. 2002 Feb;32(2):521-9 [11828369.001]
  • [Cites] Hematol J. 2002;3(1):32-7 [11960393.001]
  • [Cites] Leukemia. 1999 Feb;13(2):230-40 [10025897.001]
  • [Cites] Oncogene. 2004 Dec 9;23(57):9220-9 [15516985.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):529-35 [15645140.001]
  • [Cites] Leuk Res. 2005 Apr;29(4):381-7 [15725471.001]
  • [Cites] J Autoimmun. 2005 Aug;25(1):13-20 [15998581.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2002-10 [15941918.001]
  • [Cites] Oncogene. 2005 Sep 5;24(39):6035-46 [16155610.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2769-80 [15914562.001]
  • [Cites] Virol J. 2004;1:5 [15507126.001]
  • [Cites] PLoS Med. 2005 Dec;2(12):e343 [16253012.001]
  • [Cites] Blood. 2006 Jan 1;107(1):167-75 [16131564.001]
  • [Cites] Oncologist. 2006 Mar;11(3):263-73 [16549811.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4834-40 [16484592.001]
  • [Cites] J Clin Lab Immunol. 2004-2005;53:1-12 [16805321.001]
  • [Cites] Blood. 2006 Oct 15;108(8):2632-41 [16614248.001]
  • [Cites] AIDS Res Hum Retroviruses. 2003 Jun;19(6):497-502 [12882659.001]
  • [Cites] Nat Immunol. 2003 Sep;4(9):835-42 [12942084.001]
  • [Cites] J Leukoc Biol. 2003 Sep;74(3):331-43 [12949236.001]
  • [Cites] Curr Opin Cell Biol. 2003 Oct;15(5):515-24 [14519385.001]
  • [Cites] BMC Bioinformatics. 2002 Aug 23;3:22 [12194703.001]
  • [Cites] Nature. 2003 Dec 11;426(6967):671-6 [14668867.001]
  • [Cites] J Immunol. 2004 Feb 1;172(3):1960-9 [14734782.001]
  • [Cites] AIDS Res Hum Retroviruses. 2004 Feb;20(2):227-33 [15018711.001]
  • [Cites] J Gen Virol. 2004 May;85(Pt 5):1065-76 [15105524.001]
  • [Cites] Bioinformatics. 2004 Jun 12;20(9):1462-3 [14962933.001]
  • [Cites] Oncogene. 2004 Jun 17;23(28):4818-27 [15122313.001]
  • [Cites] Exp Hematol. 2004 Sep;32(9):806-14 [15345281.001]
  • [Cites] J Immunol. 1981 Sep;127(3):1024-9 [6790607.001]
  • [Cites] Medicine (Baltimore). 1987 Sep;66(5):397-405 [3626848.001]
  • [Cites] Blood. 1988 Mar;71(3):822-4 [3345349.001]
  • [Cites] J Immunol. 1988 Sep 15;141(6):1963-9 [3049797.001]
  • [Cites] Leukemia. 1992 May;6(5):465-9 [1317489.001]
  • [Cites] Blood. 1992 Sep 1;80(5):1116-9 [1355373.001]
  • [Cites] Blood. 1993 Jul 1;82(1):1-14 [8324214.001]
  • [Cites] Blood. 1995 Mar 1;85(5):1282-8 [7858258.001]
  • [Cites] Clin Exp Immunol. 1996 Apr;104(1):180-4 [8603525.001]
  • [Cites] Blood. 1997 Jan 1;89(1):256-60 [8978299.001]
  • [Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1;14(2):158-62 [9052725.001]
  • [Cites] Br J Haematol. 1997 Apr;97(1):123-6 [9136951.001]
  • [Cites] Immunology. 1997 Jun;91(2):204-11 [9227318.001]
  • [Cites] Nature. 1999 Oct 14;401(6754):708-12 [10537110.001]
  • [Cites] Int Rev Immunol. 1999;18(1-2):111-40 [10614741.001]
  • [Cites] Am J Dermatopathol. 2000 Feb;22(1):7-16 [10698209.001]
  • [Cites] Blood. 2002 Jul 1;100(1):178-83 [12070025.001]
  • (PMID = 18086899.001).
  • [ISSN] 0741-5400
  • [Journal-full-title] Journal of leukocyte biology
  • [ISO-abbreviation] J. Leukoc. Biol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL073429-01A1; United States / NHLBI NIH HHS / HL / R01 HL073429; United States / NHLBI NIH HHS / HL / R01 HL 073429-01A1; United States / NHLBI NIH HHS / HL / R01 HL073429-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ NIHMS83527; NLM/ PMC2629660
  •  go-up   go-down


94. Chuka-Okosa CM, Uche NJ, Kizor-Akaraiwe NN: Orbito-ocular neoplasms in Enugu, South-Eastern, Nigeria. West Afr J Med; 2008 Jul;27(3):144-7
HIV InSite. treatment guidelines - Ophthalmic Manifestations of HIV .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this era of HIV pandemic, an increase in the frequency of AIDS-related orbito-ocular neoplasms has also been reported.
  • Retinoblastoma was the most commonly occurring neoplasm accounting for 25.6% of all the tumours; followed by squamous cell carcinoma of the conjunctiva which was seen in 5 (11.6%) of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19256317.001).
  • [ISSN] 0189-160X
  • [Journal-full-title] West African journal of medicine
  • [ISO-abbreviation] West Afr J Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


95. Lan K, Murakami M, Bajaj B, Kaul R, He Z, Gan R, Feldman M, Robertson ES: Inhibition of KSHV-infected primary effusion lymphomas in NOD/SCID mice by gamma-secretase inhibitor. Cancer Biol Ther; 2009 Nov;8(22):2136-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary effusion lymphoma (PEL) is a common cancer in AIDS patients closely associated with Kaposi's sarcoma-associated herpesvirus (KSHV).
  • Our study provides further evidence to suggest that targeted downregulation of abnormal Notch signaling has therapeutic potential for KSHV related primary effusion lymphomas.
  • [MeSH-major] Amyloid Precursor Protein Secretases / antagonists & inhibitors. Dipeptides / therapeutic use. Herpesviridae Infections. Herpesvirus 8, Human / pathogenicity. Lymphoma, Primary Effusion / drug therapy. Neoplasm Proteins / antagonists & inhibitors. Receptor, Notch1 / antagonists & inhibitors. Tumor Virus Infections

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Biol Ther. 2009 Nov;8(22):2144-6 [20068386.001]
  • (PMID = 19783901.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Grant] United States / PHS HHS / / A1067037; United States / NCI NIH HHS / CA / CA091792; United States / NCI NIH HHS / CA / CA108461; United States / NIDCR NIH HHS / DE / DE017338
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral; 0 / Dipeptides; 0 / N-(N-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl ester; 0 / Neoplasm Proteins; 0 / Notch1 protein, mouse; 0 / Nuclear Proteins; 0 / Receptor, Notch1; 0 / latency-associated nuclear antigen; EC 3.4.- / Amyloid Precursor Protein Secretases
  •  go-up   go-down


96. Gwede CK, Pow-Sang J, Seigne J, Heysek R, Helal M, Shade K, Cantor A, Jacobsen PB: Treatment decision-making strategies and influences in patients with localized prostate carcinoma. Cancer; 2005 Oct 1;104(7):1381-90
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Long-term data are needed to evaluate distress and decisional regret as patients experience treatment-related chronic side effects and efficacy outcomes.
  • Decision-making aids or other interventions to reduce decisional difficulty and emotional distress during decision making were indicated.
  • [MeSH-major] Brachytherapy / methods. Neoplasm Invasiveness / pathology. Patient Satisfaction. Prostatectomy / methods. Prostatic Neoplasms / pathology. Prostatic Neoplasms / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Attitude to Health. Decision Making. Follow-Up Studies. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prospective Studies. Risk Assessment. Stress, Psychological

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080181.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


97. Rajput S, Wilber A: Roles of inflammation in cancer initiation, progression, and metastasis. Front Biosci (Schol Ed); 2010;2:176-83

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Roles of inflammation in cancer initiation, progression, and metastasis.
  • Inflammatory cells and signals contribute to the initiation and development of cancer.
  • In fact, persistent inflammatory conditions resulting from infection or injury can exist before a normal cell is transformed into a cancer cell.
  • Alternatively, cancer development unrelated to inflammation can stimulate the development of an inflammatory microenvironment that promotes tumor cell proliferation.
  • Whether chronic or tumor-derived, inflammation and inflammation-related stimuli within the tumor microenvironment permits proliferation and survival of cancer cells, promotes blood and lymphatic vessel formation, and aids in invasion and metastasis.
  • The inflammatory status of the tumor microenvironment can act to quell the body's natural immune response and effectively ameliorate a positive response to many commonly used anti-cancer antibodies and chemotherapeutic agents.
  • New evidence suggests that the molecular pathways and consequences of inflammation specifically related to the tumor microenvironment are starting to be understood.
  • [MeSH-major] Cytokines / metabolism. Inflammation / complications. Neoplasm Metastasis / physiopathology. Neoplasms / etiology. Signal Transduction / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20036938.001).
  • [ISSN] 1945-0524
  • [Journal-full-title] Frontiers in bioscience (Scholar edition)
  • [ISO-abbreviation] Front Biosci (Schol Ed)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / Hypoxia-Inducible Factor 1; 0 / NF-kappa B; EC 1.14.13.39 / Nitric Oxide Synthase Type II; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


98. Harper CE, Patel BB, Cook LM, Wang J, Shirai T, Eltoum IA, Lamartiniere CA: Characterization of SV-40 Tag rats as a model to study prostate cancer. BMC Cancer; 2009 Jan 26;9:30
Hazardous Substances Data Bank. TESTOSTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization of SV-40 Tag rats as a model to study prostate cancer.
  • BACKGROUND: Prostate cancer is the second most frequently diagnosed cancer in men.
  • Animal models that closely mimic clinical disease in humans are invaluable tools in the fight against prostate cancer.
  • This model, however, has not been extensively characterized; hence we have investigated the ontogeny of prostate cancer and determined the role of sex steroid receptor and insulin-like growth factor-1 (IGF-1) signaling proteins in the novel SV-40 Tag rat.
  • Immunoassay techniques were employed to measure cell proliferation, apoptosis, and sex steroid receptor and growth factor signaling-related proteins.
  • RESULTS: Prostatic intraepithelial neoplasia (PIN) and well-differentiated prostate cancer developed as early as 2 and 10 weeks of age, respectively in the ventral prostate (VP) followed by in the dorsolateral (DLP).
  • CONCLUSION: The rapid development of PIN and prostate cancer in conjunction with the large prostate size makes the SV-40 Tag rat a useful model for studying prostate cancer.
  • This study provides evidence of the role of sex steroid and growth factor proteins in prostate cancer development and defines appropriate windows of opportunity for preclinical trials and aids in the rational design of chemoprevention, intervention, regression, and therapeutic studies using prostate cancer rodent models.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Urology. 1999 Dec;54(6):1112-9 [10604719.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2203-8 [10786685.001]
  • [Cites] Methods Mol Biol. 2000;149:III-IV, 1-413 [11028258.001]
  • [Cites] Cancer Res. 2001 Jun 15;61(12):4693-700 [11406539.001]
  • [Cites] Reprod Fertil Dev. 2001;13(4):241-52 [11800163.001]
  • [Cites] Carcinogenesis. 2002 Mar;23(3):463-7 [11895861.001]
  • [Cites] J Urol. 2002 Jul;168(1):9-12 [12050481.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1099-106 [12122101.001]
  • [Cites] Prostate. 2003 May 15;55(3):219-37 [12692788.001]
  • [Cites] Cancer Sci. 2003 Feb;94(2):153-7 [12708490.001]
  • [Cites] Cancer Res. 2004 Mar 15;64(6):2270-305 [15026373.001]
  • [Cites] Mol Cell Endocrinol. 2004 Apr 30;219(1-2):171-80 [15149738.001]
  • [Cites] J Endocrinol. 1968 Apr;40(4):485-91 [5643421.001]
  • [Cites] Science. 1974 Dec 27;186(4170):1213-5 [4432067.001]
  • [Cites] Arch Int Physiol Biochim. 1975 May;83(2):239-53 [54056.001]
  • [Cites] Nature. 1979 Mar 15;278(5701):261-3 [218111.001]
  • [Cites] Cell. 1979 May;17(1):43-52 [222475.001]
  • [Cites] Acta Endocrinol (Copenh). 1981 Jan;96(1):127-35 [7456981.001]
  • [Cites] Cell. 1988 Jul 15;54(2):275-83 [2839300.001]
  • [Cites] J Histochem Cytochem. 1989 Jan;37(1):105-13 [2461979.001]
  • [Cites] Cell. 1990 Jan 12;60(1):167-76 [2153055.001]
  • [Cites] J Urol. 1993 Aug;150(2 Pt 1):379-85 [8326560.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Apr 11;92(8):3439-43 [7724580.001]
  • [Cites] J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26 [8757191.001]
  • [Cites] Cancer Res. 1996 Sep 15;56(18):4096-102 [8797572.001]
  • [Cites] J Clin Endocrinol Metab. 1996 Oct;81(10):3774-82 [8855837.001]
  • [Cites] Curr Opin Cell Biol. 1997 Apr;9(2):180-6 [9069255.001]
  • [Cites] J Urol. 1997 Jul;158(1):222-7 [9186364.001]
  • [Cites] Cancer Res. 1997 Nov 1;57(21):4687-91 [9354422.001]
  • [Cites] Br J Cancer. 1997;76(9):1115-8 [9365156.001]
  • [Cites] Science. 1998 Jan 23;279(5350):563-6 [9438850.001]
  • [Cites] J Natl Cancer Inst. 1998 Jun 17;90(12):911-5 [9637140.001]
  • [Cites] Endocrinology. 1999 May;140(5):1984-9 [10218945.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5458-63 [10318905.001]
  • [Cites] Br J Cancer. 1999 Jun;80(7):930-4 [10362098.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):7088-92 [10359843.001]
  • [Cites] Natl Cancer Inst Monogr. 1963 Oct;12:1-27 [14072991.001]
  • [Cites] Prostate. 2005 Feb 1;62(2):148-64 [15389804.001]
  • [Cites] Cancer Sci. 2005 Apr;96(4):221-6 [15819720.001]
  • [Cites] Carcinogenesis. 2005 Jun;26(6):1109-16 [15731164.001]
  • [Cites] Ann N Y Acad Sci. 2006 Nov;1089:1-13 [17261752.001]
  • [Cites] Cancer Sci. 2007 Apr;98(4):471-7 [17284254.001]
  • [Cites] Prostate. 2007 Oct 1;67(14):1576-89 [17705241.001]
  • (PMID = 19171036.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 47888; United States / NCI NIH HHS / CA / NIH-NCI-P20-CA93753-03
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Androgen-Binding Protein; 0 / Antigens, Polyomavirus Transforming; 0 / Neoplasm Proteins; 0 / probasin; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 5H7I2IP58X / boldenone; 67763-96-6 / Insulin-Like Growth Factor I
  • [Other-IDs] NLM/ PMC2639608
  •  go-up   go-down


99. Attia S, Dezube BJ, Torrealba JR, Sosman JM, McHaffie DR, Pfau PR, Bailey HH, Kozak KR: AIDS-related Kaposi's sarcoma of the gastrointestinal tract. J Clin Oncol; 2010 Jun 01;28(16):e250-1
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AIDS-related Kaposi's sarcoma of the gastrointestinal tract.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active / methods. Biopsy, Needle. Doxorubicin / therapeutic use. Drug Therapy, Combination. Follow-Up Studies. Gastrointestinal Neoplasms / drug therapy. Gastrointestinal Neoplasms / etiology. Gastrointestinal Neoplasms / pathology. HIV Infections / complications. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Immunohistochemistry. Male. Neoplasm Staging. Risk Assessment. Severity of Illness Index. Treatment Outcome


100. Szucs-Farkas Z, Peltzer J, Berger D, Braunschweig M: Aggressive lymphoma of the skull in a patient with AIDS. JBR-BTR; 2005 May-Jun;88(3):152-3
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive lymphoma of the skull in a patient with AIDS.
  • [MeSH-major] Bone Neoplasms / radiography. Cerebellar Neoplasms / radiography. Lymphoma, AIDS-Related / radiography. Skull / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Adult. Arachnoid Cysts / radiography. Biopsy. Cerebral Ventriculography. Cranial Fossa, Posterior / pathology. Cranial Fossa, Posterior / radiography. Diagnosis, Differential. Disease Progression. Female. HIV Seropositivity / pathology. HIV Seropositivity / radiography. Humans. Incidental Findings. Neoplasm Invasiveness / pathology. Occipital Bone / pathology. Parietal Bone / pathology. Substance Abuse, Intravenous / complications

  • Genetic Alliance. consumer health - AIDS-HIV.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038238.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down






Advertisement